PROTEIN KINASE INHIBITOR COMPOUND, ITS PHARMACEUTICAL COMPOSITION AND ITS USE

专利摘要:
protein kinase inhibitor compound, its pharmaceutical composition and use. the present invention relates to a new class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or unregulated kinase activity ' particularly diseases or disorders that involve abnormal activation of b-raf.
公开号:BR112012004453A2
申请号:R112012004453-2
申请日:2010-08-27
公开日:2021-03-09
发明作者:Shenlin Huang；Novartis AG；Xianmig Jin；Zuosheng Liu；Daniel Poon；John E. Tellew；Yongqin Wan；Xing Wang；Yongping Xie
申请人:Array Biopharma, Inc.；
IPC主号:

专利说明:

[0001] [0001] The present patent application claims priority benefit to the Provisional Patent Applications US 61/238, 073, unpipitated on 28th of April 2009 and 61/313, 039, filed on March 11th, 2010. The full descriptions of these patent applications are hereby incorporated by reference in their entirety and for all purposes.
[0002] [0002] The present invention relates to a new class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or unregulated kinase activity, particularly diseases or disorders that involve the abnormal activation of B-Raf. Background
[0003] [0003] Protein kinases represent a large family of proteins, which play a central role in regulating a wide variety of cell processes and maintaining control over cell function. A partial, non-limiting list of these kinases includes: tyrosine kinase receptors, such as platelet-derived receptor kinase growth factor (PDGF-R), the nerve growth factor receptor, trkB, Met, and the receptor fibroblast growth factor, FGFR3; non-receptor tyrosine kinases, such as Abl and the Bcr-Abl, Lck, Csk, Fes, Bmx and c-src fusion kinase; and serine / threonine kinases, such as B-Raf, SGK, MAP kinases (e.g., MKK4, MKKG6, etc.) and SAPK2 a, SAPK2 é and SAPK3.
[0004] [0004] The new compounds of the present invention inhibit the activity of B-Raf or mutant forms thereof (for example, V600E) and are therefore expected to be useful in the treatment of disease as a B-Raf. SUMMARY OF THE INVENTION
[0005] [0005] In one aspect, the present invention relates to the compounds of Formula |: R3 IN THE FACTION! Rix A Z R6s O N N í “y
[0006] [0006] Y is selected from N and CR;
[0007] [0007] R1 is selected from hydrogen, -X1R8a, -X + OX2Rga, —-X1C (O) NRgaRgo, -X1NRgaX2Rg8t, -X: NRgaC (O) X20Rgt, -X: NRgaC (O) X2 NRseaRgp, - X: NRgaS (O) o0-2R81; where each X: is independently C1-4alkylene; and X, optionally has 1 to 3 hydrogens substituted with a group selected from hydroxy, halo, cyano, C1-alkyl, -C1-4alkyl substituted by halo, Ci4alkoxy and -Cialoxy substituted by halo; X> is selected from the bond and C1- alkylene; where Rea E Rey are independently selected from hydrogen, C1-salkyl, -C1-salkyl substituted by halo, Ca-gcycloalkyl, heteroaryl and C3a.gheterocycloalkyl; where the cycloalkyl, heterocycloalkyl or heteroaryl of Rga or Reg 'is optionally substituted with 1 to 3 radicals independently selected from amine, cyano, C1-4alkyl, C1-4alkoxy, -Calkylyl substituted by halo and -C1- alkoxy substituted by halo; with the certainty that Re, is not hydrogen when R: is selected from -XA-NHC (O) OR, and -X1NRsg2aS (O) o-2R8b;
[0008] [0008] R2, R3, Rs and Rg are independently selected from hydrogen, halo, cyano, C1-4alkyl, -C1-4alkyl substituted by halo, C1-4 alkoxy and -Ci4alkoxy substituted by halo; with the certainty that when Rs is fluorine and R1 is selected from hydrogen, -X Rea, - X1O0OX2R8a, -X: C (O) NRgaRgh, -XINRgaX2R8tr, -X1NRgaC (O) X2O0R86 E - XINRgaS (O) o -2R8v, R3 and Rg are not both hydrogen;
[0009] [0009] Ra is selected from -R9 and -NR1oR11; where Ro is selected from Ci.salquila, Ca.gcycloalkyl, Ca-sheterocycloalkyl, aryl and heteroaryl; wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl of Ro is optionally substituted with 1 to 3 radicals independently selected from halo, cyano, C1-4alkyl, -Ci4alkyl substituted by halo, Cisalkoxy and halo-substituted -Ci4alkoxy; and Rio and R11 are independently selected from hydrogen and Ro;
[0010] [0010] R7 is selected from hydrogen, Cialkyl, Ca-5 cycloalkyl and C3.sheterocycloalkyl; wherein said alkyl, cycloalkyl or heterocycloalkyl of R; it is optionally substituted with 1 to 3 radicals independently selected from halo, cyan, hydroxyl, Cyalkyl, -C1-4alkyl substituted by halo, Cisaloxy and -C1i4aloxy substituted by halo; and N-oxide derivatives, prodrug derivatives, protected derivatives, tautomers, individual isomers and mixture of isomers thereof; and the pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds.
[0011] [0011] In a second aspect, the present invention provides a pharmaceutical composition that contains a compound of Formula | or an N-oxide derivative, individual isomers and mixture of isomers, or a pharmaceutically acceptable salt thereof, in admixture with one or more suitable excipients.
[0012] [0012] In a third aspect, the present invention provides a method of treating a disease in an animal in which the inhibition of kinase activity, in particular B-Raf activity, can prevent, inhibit or improve pathology and / or symptomatology of the diseases, which method includes administering to the animal a therapeutically effective amount of a compound of Formula | or an N-oxide derivative, individual isomers and mixture of isomers, or a pharmaceutically acceptable salt thereof.
[0013] [0013] In a fourth aspect, the present invention provides the use of a compound of Formula | in the manufacture of a medication for the treatment of a disease in an animal in which kinase activity, in particular B-Raf | activity, particularly mutant B-raf (for example, V600E), contributes to the pathology and / or symptomatology of the disease.
[0014] [0014] In a fifth aspect, the present invention provides a process for the preparation of compounds of Formula | and N-oxide derivatives, prodrug derivatives, protected derivatives, individual isomers and mixtures of isomers, and pharmaceutically acceptable salts thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] [0015] Figure 1: Figure 1 illustrates that the addition of a small molecule MEK inhibitor can reverse the induced ERK signaling, cell growth and transformation caused by a small molecule Raf inhibitor.
[0016] [0016] "Alkyl" as a group and as a structural element of other groups, for example halo-substituted alkyl and alkoxy, can be either straight chain or branched. C1-4-alkoxy includes, methoxy, ethoxy, and the like. -C1-4alkyl substituted by Halo and the alkyl group (branched or unbranched) in which any of the hydrogens can be replaced with a halogen. For example, halo-substituted C1-4alkyl may be trifluoromethyl, difluorethyl, pentafluoroethyl, and the like. Similarly, the hydroxy-substituted -C1-6alkyl and alkyl group (branched or unbranched) in which any of the hydrogens can be replaced with a hydroxyl. For example, hydroxy substituted C1-6alkyl includes 2-hydroxyethyl, and the like. Similarly, C1-6alkyl substituted by cyano and alkyl group (branched or unbranched) in which any of the hydrogens can be substituted with cyan.
[0017] [0017] "Arila" means a fused monocyclic or bicyclic aromatic ring set containing six to ten carbon atoms in the ring. For example, aryl can be phenyl or naphthyl, preferably phenyl. "Arylene" means a divalent radical derived from an aryl group.
[0018] [0018] "Cycloalkyl" means a fused monocyclic, fused monocyclic, partially unsaturated, polycyclic bridged ring containing the number of atoms in the indicated ring. For example, C3-10cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.
[0019] [0019] "Heteroaryl" is as defined for the aryl above, where one or more of the members of the ring is a heteroatom. For example, heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl, quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl, benzo [1,3] dioxol, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl, oxazolyl, tetrazolyl, isoxazolyl, tzazolyl, isoxazolyl, tetrazolyl, isoxazolyl, , pyrazolyl, thienyl, etc.
[0020] [0020] "Heterocycloalkyl" means cycloalkyl, as defined in the present patent application, provided that one or more of the indicated ring carbons are replaced by a portion selected from among O, N =, NR, C (O), S, S (O) or S (O) 2, where R is hydrogen, C1-4alkyl or a nitrogen protecting group. For example, C3- 8 heterocycloalkyl as used in this patent application to describe compounds of the present invention includes 2H-pyran, 4H-pyran, piperidine, 1,4-dioxane, morpholine, 1,4-dithian, thiomorpholine, imidazolinid -2-one, tetrahydrofuran, piperazine, 1,3,5-tritiano, pyrrolidine, pyrrolidinyl-2-0na, piperidine, piperidinone, 1,4-dioxa-8-aza-spiro [4,5] dec - 8-line, etc.
[0021] [0021] "Halogen" (or halo) represents fluorine, chlorine, bromine or iodine.
[0022] [0022] "pMEK" means phosphorylated Mek.
[0023] [0023] "pERK" means phosphorylated ERK.
[0024] [0024] "Treating", "treatment" and "treating" refer to a method of relieving or reducing a disease and / or accompanying symptoms.
[0025] [0025] The compounds of the present invention are named using ChembDraw Ultra (Version 10.0) and / or Generator Name ChemAxon (JChem Version 5.3.1.0). Description of preferred modalities
[0026] [0026] The present invention provides compounds, compositions and methods for the treatment of kinase-related diseases, in particular diseases related to a B-Raf kinase, for example, metastatic melanomas, solid tumors, brain tumors, such as glioblastoma multiforme ( GBM), acute myeloid leukemia (AML), prostate cancer, gastric cancer, papillary thyroid carcinoma, low-grade ovarian carcinoma and colorectal cancer.
[0027] [0027] In one embodiment, with reference to the compounds of Formula |, R1 is selected from X1IR8a and XINHC (O) OR8b; wherein each X1 is independently C1-4alkylene; and X1, optionally, has 1 to 3 hydrogen atoms replaced with a group selected from hydroxy, halo, cyano, C1-4alkyl and C1-4alkyl substituted by halo; where R8a and R8b are independently selected from hydrogen and C1-6alkyl; with the proviso that R8b is not hydrogen when R1 is -X1INHC (O) OR8b;
[0028] [0028] In another embodiment are the compounds of Formula la: R3 Y, / 2 NA o, = If Ra
[0029] [0029] In an additional modality, Ra is -R9; wherein Rg is selected from C1-3alkyl and Ca-.cycloalkyl; wherein said alkyl or cycloalkyl of Rg is optionally substituted with 1 to 3 radicals independently selected from halo and -Ci4alkyl substituted by halo.
[0030] [0030] In an additional modality, R2 is selected from hydrogen and fluorine; R3 is selected from chlorine, fluorine and methyl; Rs is selected from hydrogen, from chlorine and fluorine; Y is selected from N and CR; and R «is selected from hydrogen and fluorine.
[0031] [0031] In an additional embodiment are the compounds selected from: N - [(2S) -1- (f4- [3- (3-chloro-5-methanesulfonamidophenyl) - 1- (propan-2-yl ) -1H-pyrazol-4-yl] pyrimidin-2-yl ') amino) propan-2-yl | methyl carbamate; N - [(2S) -1 - [(4- (13- [2-fluor-3- (propane-1-sulfonamido) phenyl] -1- (propan-2-yl) -1H-pyrazol-4-yl ) pyrimidin-2-yl) amino] propan-2-yl | methyl carbamate; N - [(2S) -1- (f4- [3- (2-fluor-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] Jpirimidin-2-ilyamino ) propan-2-yl | carbamate - methyl; N - [(28S) -1 - [(4- (3- [3-chloro-5- (propane-1-sulfonamido) phenyl] -1- (propan-2-yl) -1H-pyrazol-4 -yl) pyrimidin-2-yl) amino] propan-2-yl | carbamate - methyl; N - [(2S) -1- (f4- [3- (2,6-difluoro-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] Jpirimidin-2 -ilyamino) propan-2-yl | carbamate - methyl; - N - [(2S) -1 - [(4-13- [2,6-difluoro-3- (propane-1-sulfonamido) phenyl] -1- (propan-2-yl) -1H-pyrazole-4 -yl) pyrimidin-2-yl) amino] propan-2-yl | methylamine carbamate N - [(28) -1 - ([4- (3- (2-fluorine-3 - [(3,3,3 methyl-trifluorpropane) sulfonamido] phenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl) pyrimidin-2-ylJamino) propan-2-illcarbamate; N - [(2S) -1- (f4- [3- (3-chloro-2-methanesulfonami- dopiridin-4-yl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin -2-yl) amino) propan-2-yl | methyl carbamate; N - [(28S) -1 - ((4- [3- (3-fluoro-2-methanesulfone-midopyridin-4-yl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl) amino) propan-2-yl | methyl carbamate; N - [(2S) -1- (f4- [3- (2-chloro-3-ethanesulfo-
[0032] [0032] In another embodiment are the compounds of Formula lb: it is NH ns TAAO OX
[0033] [0033] In an additional embodiment are the compounds selected from: N - [(28S) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfone-midophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl) amino) methyl propan-2-illcarbamate; N - [(2S) -1 - ((4- [3- (2,5-difluoro-3-methanesulfone-midophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin- Methyl 2-yl) amino) propan-2-illcarbamate; N - [(2S) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfon-phonamidophenyl) -1-ethyl-1H-pyrazol-4-yl] pyrimidin-2-yl) yamino ) propan-2-yl] methyl carbamate; N - [(2S) -1- (f4- [3- (2-fluor-3-methanesulfonamido-5-methylphenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2 methyl -amino <amino) propan-2-ylcarbamate; N - [(2S) -1 - ((4- [3- (2-chloro-3-methanesulfone-mido-S5-methylphenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl> <> amino) propan-2-yl | methyl carbamate; N - [(2S) -1- (f4- [3- (2-chloro-5-fluor-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl;) <amino) propan-2-yl | methyl carbamate; N - [(2R) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2 -yl) amino) propan-2-yl | methyl carbamate; N - [(2S) -1- (f4- [3- (2,5-dichloro-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl ) amino) methyl propan-2-yl | carbamate; and N - [(28S) -1 - ((4- [3- (5-chloro-2-fluoro-3-methanesulfonamidophenyl) -1H-pyrazol-4-yl] pyrimidin-2-yl) amino) propan-2 -yl | methyl carbamate.
[0034] [0034] In another embodiment are the compounds selected from: N- [5-chloro-3- (4- (2 - [(2-cyanoethyl) amino] pyrimidin-4-yl) -1- ( propan-2-yl) -1H-pyrazol-3-yl) -2-fluorophenyl]] methanesulfonamide; N- (5-chloro-3- [4- (2 - [[2- (dime-tilamino) ethylJamino) pyrimidin-4-yl) -1- (propan-2-yl) - 1H-pyrazol-3-i1 ] -2-fluorophenyl) methanesulfonamide; N- (5-chloro-2-fluoro-3- 14- [2- (methylamino) pyrimidin-4-i1] -1- (propan-2-yl) -1H-pyrazol-3-yl) Yfenil) me- tanosulfonamide; and N- (3- [4- (2-amino-pyrimidin-4-yl) -1- (propan-2-i1) -1H-pyrazol-3-i1] -5-chloro-2-fluorophenyl) methanesul- phonamide.
[0035] [0035] In an additional embodiment are the compounds selected from the Examples and Tables, below.
[0036] [0036] In an additional modality are the intermediate compounds selected from: 3-Bromo-5-chloro-2-fluoraniline; cyano- (2-methylthio-pyrimidin-4-yl) -acetic acid tert-butyl ester; 1-Isopropyl-4- (2- (methylthio) pyrimidin-4-yl) -1H-pyrazol-3-amine; - 2 - ((2-Benzylide-1-ethylhydrazinyl) methylene) -malononitrile; 1- (3-Amino-1-isopropyl-1H-pyrazol-4-yl) ethanone; 1- (3-sludge-1-isopropyl-1H-pyrazol-4-yl) ethanone; 1- (3-sludge-1-ethyl-1H-pyrazol-4-yl) ethanone; 1- (3-sludge-1-methyl-1H-pyrazol-4-yl) ethanone; 3- (Dimethylamino) -1- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) prop-2-en-1-one; 3- (Dimethylamino) -1- (3-iodo-1-ethyl-1H-pyrazol-4-yl) prop-2-en-1-one; 3- (Dimethylamino) -1- (3-iodo-1-methyl-1H-pyrazol-4-yl) prop-2-en-1-one; 4- (3-sludge-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-amine; 4- (3-sludge-1-ethyl-1H-pyrazol-4-yl) pyrimidin-2-amine; - 4- (3-sludge-1-methyl-1H-pyrazol-4-yl) pyrimidin-2-amine; 4- (3-sludge-1-isopropyl-1H-pyrazol-4-yl) pyrimi-din-2-o] 1; 2-Chloro-4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidine; (S) -Methyl 1- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate; - (R) -Methyl 1- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate; (S) -tert-butyl 1- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate; 3- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propanenitrile; 4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) - N-methylpyrimidin-2-amine; N- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimi-din-2-yl) -N2, No.-dimethylethane-1,2-diamine; N- (3-bromo-2 4-difluorfenyl) oropane-1-sulfonamide; 3-Fluorine-4-iodopyridin-2-amine; - 3-chloro-4-iodopyridin-2-amine; - 3-Bromo-2,5,6-trifluoriniline; 2,4-Dibromo-3,6-dichloroaniline; 3-bromo-2-chloro-5-methylaniline; 3-bromo-2,5-difluoraniline; 3-Bromo-5-chloro-2-fluorbenzoic acid; 3-Terc-butyl bromo-5-chloro-2-fluorophenylcarbamate; Tert-butyl 3-bromo-2-fluoro-5-methylphenylcarbamate; 5-chloro-2-fluoro-3- (4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl) Terc-butyl phenylcarbamate; 2,6-diflúor-3- (4.4,
[0037] [0037] The present invention also includes all isotopic variations as appropriate for the compounds of the present invention, or pharmaceutically acceptable salts. An isotopic variation of a compound of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass normally found in nature . Examples of isotopes that can be incorporated into the compounds of the present invention and pharmaceutically acceptable salts thereof include, but are not limited to isotopes of hydrogen, carbon, nitrogen and oxygen, such as 2H, 3H, 11C, 13C, 14C, 15N, 170,180, 358, 18F, and 36CI 1231. Certain isotopic variations of the compounds of the present invention and pharmaceutically acceptable salts thereof, for example, those in which a radioactive isotope, such as 3H or 14C is incorporated, are useful in drugs and / or substrate studies for tissue distribution. In specific examples, isotopes 3H and 14C can be used to facilitate
[0038] [0038] Some Raf inhibitors, in addition to increasing MEK and ERK, in wild-type B-Raf cells, also induce cell growth in cancer cells from transformation and cause and growth in fibroblasts. Downstream signaling induction was previously attributed to published Raf route feedback loops. However, induction of pMEK and pERK can occur within minutes of treatment with a Raf inhibitor, even before reported feedback phosphorylation cases are seen in B-Raf and C-Raf. The induction of signaling and cell growth occurs both in a biphasic pattern, with concentrations of low-cost compounds (0.01 to 0.1 u M) that cause maximum induction, and higher concentrations of compounds (1 to 10 u M) causing less deep induction. Such a biphasic pattern is also observed in biochemical tests with purified wild-type B-Raf or C-Raf and is suggestive of a mechanism involving the interaction of two signaling subunits . In addition, Raf dimerization can regulate PpMEK, not through trans-phosphorylation of Raf molecules but presumably through conformational kinase activation. Consistent with this model, treatment with a Raf inhibitor induces the formation of B-Raf / C-Raf dimers in cells. In addition, A- or B-Raf knockdown with siRNA does not exempt the induction of the Raf and pMEK PERK inhibitor, and C-Raf knockdown only slightly decreases the induction. Notably, K-Ras knockdown in mutant K-Ras cells also only slightly decreases induction, which implies that this effect is not mediated mainly by Ras. Taken together, the data suggest a model in which the inhibitor of binding to a Raf molecule induces dimerization and conformational activation of a Raf partner molecule in the dimer. This may explain why wild-type Raf and Ras mutant tumors are insensitive to selective Raf kinase inhibitors and may also have important implications for toxicity, since the induction of strong mitogenic signaling could lead to hyper proliferation of tissues normal. Understanding the induction mechanism of the Raf inhibitor can lead to the design of improved inhibitors.
[0039] [0039] The addition of a MEK inhibitor in combination with a Raf inhibitor leads to a significant inhibition of ERK and, consequently, a decrease in cell proliferation and transformation. Since MEK inhibitor treatments alone led to dose-limiting toxicities in the clinic, a Raf plus the combination of MEK inhibitor may represent a superior treatment strategy.
[0040] The present invention also includes combinations of BRAF inhibitors described in the present invention with other agents. In particular, the present invention provides combinations with MEK1 / 2 inhibitors. Figure 1 illustrates that the addition of a small molecule MEK inhibitor can reverse the induced ERK signaling, cell growth and transformation caused by a small molecule Raf inhibitor. For example, a compound of Formula | (compound 9 of the present invention, namely: 1- (4- (3- (5-chloro-2-fluor-3- (methylsulfonamido) phenyl) -1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2 (ilamino) propan-2-ylcarbamate) of ((S) -methyl can lead to an induction of cell proliferation, seen as a negative inhibition in Figure 1 of a Glo Titer assay cell using the SWB620 cell line. Y shows negative and positive inhibition, each experiment is presented as a series of 9 serial dilutions between 10 and 0.002 1. Compound A1 N- (4-methyl-3- (1- (6- (4-methylpiperazin -1- ylamino) pyrimidin-4-i1) -1H-imidazol-2-ylamino) phenyl) -3- (trifluoromethyl) Denzamide) is a control, A3 is a MEK inhibitor (PDO325901). Compound 9 is tested in the absence and in the presence of 1uM, 0.1uMe0.01uM of the MEK A3 inhibitor. Pharmacology and Utility
[0041] [0041] The compounds of the present invention modulate kinase activity and, as such, are useful for treating diseases or disorders in which kinases contribute to the pathology and / or symptomatology of the disease. Examples of kinases that are inhibited by the compounds and compositions described in the present invention and against which the methods described in this invention are useful include, but are not limited to, B-Raf, including mutant forms of B-Raf.
[0042] [0042] The mitogen-activated protein kinase (MAPK) pathway mediates the activity of a number of effector molecules that coordinate to control cell proliferation, survival, differentiation and migration. Stimulation of cells, for example, growth factors, cytokines or hormonal results in the plasma of Rcomo is associated with the Ras membrane, making it bound to GTP and, in this way, activated to recruit Raf. This interaction induces Raf kinase activity which leads to direct MAPK / ERK (MEK) phosphorylation, which in turn phosphorylates the kinase related to the extracellular signal (ERK). Activated ERK then phosphorylates a wide variety of effector molecules, for example, kinases, phosphatases, transcription factors and cytoskeletal proteins. Therefore, the Ras-Raf-MEK-ERK signaling pathway transmits signals from cell surface receptors to the nucleus, which is essential, for example, in proliferation.
[0043] [0043] The role and essential position of RAF in many signaling pathways has been demonstrated in studies using unregulated and dominant inhibitors of Raf mutants in mammalian cells, as well as from studies using biochemical and genetic techniques , for model organisms. In the past, the focus on Raf being a target of the anti-tumor drug focused on its function as a downstream effector of Ras. However, recent findings suggest that Raf may play a prominent role in the formation of certain tumors without the need for an oncogenic Ras allele. In particular, the activation alleles of B-Raf and N-Ras were identified in - 70% of melanomas, 40% of papillary thyroid carcinoma, 30% of low-grade ovarian carcinoma, and 10% of cancers of the colon. Mutations in K-Ras occur in approximately 90% of pancreatic cancers. Most B-Raf mutations are found within the kinase domain, with a single substitution (V600E) corresponding to at least 80%. Mutable B-Raf proteins activate the Raf-MEK-ERK pathway either through increased kinase activity, for MEK or through C-Raf activation.
[0044] [0044] Therefore, the development of a B-Raf kinase inhibitor offers a new therapeutic opportunity for the treatment of many types of human cancers, especially for metastatic melanomas, solid tumors, brain tumors, such as Glioblasma multiforme (GBM ) acute myeloid leukemia (AML), lung cancer, papillary carcinoma, low-grade ovarian carcinoma and colorectal cancer. Various Raf kinase inhibitors have been described as exhibiting efficacy in inhibiting tumor cell proliferation in vitro and / or in vivo assays (see, for example, U.S. Patent Nos.
[0045] [0045] The compounds of the present invention inhibit cell processes involving the B-Raf kinase by blocking the signal cascade in these cancer cells and ultimately inducing stasis and / or cell death.
[0046] [0046] In accordance with the foregoing, the present invention further provides a method for the prevention or treatment of lung cancer, prostate cancer, gastric cancer, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and the nervous system. In addition, the present invention further provides a method for the prevention or treatment of any of the diseases or disorders described above in an individual in need of such treatment, which method includes administering to said individual a therapeutically effective amount (See, "Admin.
[0047] [0047] In general, the compounds of the present invention will be administered in therapeutically effective amounts through any of the usual and acceptable modes known in the art, either individually or in combination with one or more therapeutic agents. A therapeutically effective amount can vary widely, depending on the severity of the disease, the age and relative health of the individual, the potency of the compound used and other factors. In general, satisfactory results are indicated to be obtained systematically in daily doses from about 0.03 to 30mg / kg by body weight. A daily dosage indicated in the larger mammal, for example humans, is in the range of about 0.5 mg to about 2000 mg, conveniently administered, for example in divided doses up to four times a day or in the form of a delay. Other unitary forms such as a suitable dosage form for oral administration comprise of ap. 1 to 500 mg of the active ingredient.
[0048] [0048] The compounds of the present invention can be administered as pharmaceutical compositions by any conventional route, in particular enterically, for example, orally, for example, in the form of tablets or capsules, or parenterally. for example, in the form of injectable solutions or suspensions, topically, for example, in the form of lotions, gels, ointments or creams, or in a nasal or suppository form. Pharmaceutical compositions comprising a compound of the present invention in free form or in a pharmaceutically acceptable salt form in association with at least one pharmaceutically acceptable carrier or diluent can be manufactured in a conventional manner by means of mixing, granulating or coating methods. .
[0049] [0049] Formulations suitable for transdermal applications include an effective amount of a compound of the present invention with a vehicle. A vehicle may include pharmaceutically acceptable absorbable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a support element, a reservoir containing the compound optionally with vehicles, optionally a rate control barrier to deliver the compound to the host's skin at a controlled rate and predetermined over an extended period of time, and means for securing the device to the skin. Transdermal matrix formulations can also be used. Formulations suitable for topical application, for example, to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well known in the art. This may contain solubilizers, stabilizers, tonicity-reinforcing agents, buffers and preservatives.
[0050] The compounds of the present invention can be administered in therapeutically effective amounts in combination with one or more therapeutic agents (pharmaceutical combinations). For example, synergistic effects can occur with other anti-tumor and anti-proliferative agents, for example, mitotic inhibitors, alkylating agents, antimetabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, inhibitors topoisomerase, biological response modifiers, antibodies, cytotoxic, anti-hormonal agents, antizcandrogens, and anti angiogenesis, kinase inhibitor, pan kinase inhibitor or growth factor inhibitor.
[0051] The compounds of the present invention can be administered in therapeutically effective amounts in combination with one or more suitable excipients selected from corn starch, potato starch, tapioca starch, starch paste, pregelatinized starch, sugars, gelatin, natural gums, synthetic gums, sodium alginate, alginic acid, gum, tragacanth, guar gum, cellulose, ethyl cellulose, cellulose acetate, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose - if, microcrystalline cellulose, magnesium aluminum silicate, polyvinyl-pyrrolidone, talc, calcium carbonate, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, agar, sodium carbonate, croscarmellose sodium , crospovidone, polacriline potassium, sodium starch glycolate, clays, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, clear mineral oil, glycerin, sor bitol, polyethylene glycol mannitol, other glycols, sodium lauryl sulfate, hydrogenated vegetable oil, peanut oil, cotton seed oil, sunflower oil, sesame oil, olive oil, corn oil, soybean oil, zinc stearate, sodium oleate, ethyl oleate, ethyl laureate, silica and combinations thereof.
[0052] [0052] An embodiment of the present invention is a method according to claim 12 or 13, further comprising administering to the individual an additional therapeutic agent. The additional therapeutic agent comprises an anti-cancer drug, a pain medication, an anti-emetic, an antidepressant or an anti-inflammatory agent. In addition, the additional therapeutic agent is a kinase inhibitor other than Raf or an inhibitor of MEK, mTOR, HSP90, AKT, PI3SK, CDK9, PAK, protein kinase C, a MAP kinase, a MAPK kinase, or ERK and is administered to the subject simultaneously with a compound of the present invention.
[0053] [0053] For example, the addition of a MEK inhibitor in combination with a Raf inhibitor leads to a significant inhibition of ERK and, consequently, a decrease in proliferation and transformation
[0054] [0054] In another embodiment of the present invention are combinations and methods of treating cancer comprising a therapeutically effective amount of a Summary of the Invention compound (Raf inhibitor) and at least one inhibitor of the MEK protein kinase.
[0055] [0055] When the compounds of the present invention are administered in conjunction with other therapies, the dosages of the co-administered compounds will, of course, vary depending on the type of co-drug employed, in the specific drug used, the condition to be treated and so on. onwards.
[0056] [0056] The present invention also provides pharmaceutical combinations, for example a kit, comprising a) a first agent which is a compound of the present invention as described in the present invention, in the free form or in the form of a pharmaceutically acceptable salt, and b) at least one co-agent. The kit may include instructions for its administration.
[0057] [0057] The terms "co-administration" or "combined administration" or similar as used in the present invention are intended to encompass the administration of selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not they are necessarily administered by the same route of administration or at the same time.
[0058] [0058] The term "pharmaceutical combination", as used in the present invention, means a product that results from mixing or combining more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The "fixed combination" means that the active ingredients, for example, a compound of Formula | and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dose. The term "non-fixed combination" means that the active ingredients, for example, a compound of Formula | and a co-agent, are both administered to a patient, as separate entities, either simultaneously, concurrently or sequentially without specific time limits, where such administration therapeutically provides effective levels of compounds 2 in the patient's body. The latter also applies to cocktail therapy, for example, the administration of 3 or more active ingredients. Processes for the production of compounds of the Invention
[0059] [0059] The present invention also includes processes for preparing the compounds of the present invention. In the reactions described, it may be necessary to protect reactive functional groups, for example, hydroxy, amino, imino, uncle or carboxy groups, when these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups can be used according to standard practice, for example, see TW Greene and PGM Wuts in "Protective Groups in Organic Chemistry", John Wiley and Sons, 1991.
[0060] [0060] The compounds of Formula | can be prepared by proceeding as in the following reaction scheme |: Reaction scheme |
[0061] [0061] Formula 2 compounds can be prepared by reacting a Formula 3 compound with an alkylating agent of general formula 4 in the presence of a suitable solvent (eg DMF, DMSO, and the like) and a suitable base (for example, potassium carbonate, sodium hydride, and the like). The reaction proceeds over a temperature range of about 0 ° C to about 150 ° C and can take up to about 24 hours to complete.
[0062] [0062] The compounds of Formula | can also be prepared by proceeding as in the following Reaction Scheme | l: Reaction Scheme Il R3 * x H nel O As Pa CS et ions - Ss Tm, AA R oo “x nÔ (OH | a N 1oR 6 8 in which R1 , R2, R3, R4, R5, and Y are as defined in the Summary of the Invention.A compound of Formula | can be synthesized by reacting a Formula 5 compound with a Formula 6 sulfonylation reagent in the presence of of a suitable base (for example, pyridine, triethylamine, 4 - (N, N-dimethylamino) pyridine, and the like) and a suitable solvent (such as pyridine, dichloromethane, 2-methylTHF, and the like). a temperature range of about 0 ° C to about 100 ° C and can take up to about 24 hours to complete. The reaction mixture is optionally further reacted to remove any of the protecting groups. sulfonylating reagent can react twice to produce a bis-sulfonyl derivative. In this example, the bis-sulfonyl compound can be co inverted into a Formula One compound by treatment with a suitable base (for example, sodium or potassium hydroxide, or sodium or potassium carbonate), in the presence of a protic solvent such as methanol or water, optionally in the presence of a co-solvent such as toluene or 2-methylTHF. The reaction takes place in a temperature range of about 20ºC to about 100ºC and can take up to about 24 hours to complete.
[0063] [0063] The compounds of Formula | can also be prepared by proceeding as in the following Reaction Scheme Ill: Reaction Scheme Ill Ra
[0064] [0064] A Formula 1 compound can also be prepared using a protocol similar to the Suzuki reaction in which the Formula 7 compound reacts with a Formula 8a compound to generate a Formula 9 compound. After deprotection of the R90 groups, a sulfonylation reaction, as described for Reaction Scheme II, generates a compound of Formula IA.
[0065] [0065] It will be appreciated by a person skilled in the art that other organometallic coupling reactions, for example, using tin reagents (Stille coupling) or zinc reagents (Negishi coupling), can also be used in place of the Suzuki coupling using the boron reagents described in Reaction Scheme Ill.
[0066] [0066] The compounds of Formula 7 can be prepared by proceeding as in the following Reaction Scheme | V:
[0067] [0067] In this example, M is a leaving group (for example, chlorine, bromine, iodine, methanesulfonyl, and the like), R50 is a leaving group (for example, iodine, bromine, chlorine, trifluoromethanesulfonyloxy, and similar - res), and R7 is as defined in the Summary of the Invention. A Formula 7 compound can be prepared by reacting a Formula 10 amine compound with a Formula 11 compound. The reaction is carried out in the presence of a suitable base (eg, triethylamine, potassium carbonate, and the like) ) in a solvent such as isopropanol, DMSO, NMP, or dioxane, at a temperature from about 25 to about 120 ° C. In some cases, other transformations of the newly introduced group R1 can subsequently be carried out to reach the desired final group R1.
[0068] [0068] Formula 11a compounds, which are a subset of Formula 11 compounds in which M is methanesulfonyl, can be prepared by proceeding as in the following Reaction Scheme V: Reaction Scheme V neo x> Ex O o + Ox SARA if ld c Ss oÊ o (16) 7) As - DMF DMA NO in KAS hd NHINH2 sl EE = AA À No as) (14) and RM Nº N = DE x Rs0 o AA NH AD Rso o KH - o TX - nº o Y À 13) R (12) R7 (11a) where R7 and R50 are as defined in the Summary of the Invention. A Formula 11a compound can be prepared by reacting a Formula 12 compound with a suitable oxidizing system (for example, m-chloroperbenzoic acid in a dichloromethane solvent, or "Oxone" in aqueous methanol, and the like), to a temperature of about -78ºC to about 50 oC. The reaction takes about 24 hours to complete.
[0069] [0069] A Formula 12 compound in which R50 is chlorine, bromine, or iodine, in turn can be prepared by reacting a Formula 13 amine compound with a suitable reagent diazotizing system (for example, nitrous acid together with a copper (|) halide salt, isoamyl nitrite together with copper (1) methylene iodide / iodide, isoamyl nitrite together with boron, iodine, and potassium iodide in acetonitrile, and the like). The reaction takes place at a temperature of about 0 to about 80 ° C, and takes about 1 to about 6 hours to complete.
[0070] [0070] A Formula 13 compound can be prepared by reacting a Formula 14 compound with a Formula 3 compound, as described for Reaction Scheme |
[0071] [0071] A Formula 14 compound can be prepared by cyclizing a Formula 15 enaminonitrile compound with hydrazine or a hydrazine salt in a suitable solvent (for example, ethanol and the like). The reaction takes place at a temperature of about 25 to about 100ºC, and can take from about 1 hour to about 24 hours to complete.
[0072] Alternatively, a Formula 13 compound can be prepared from a Formula 15 compound in a one-step process by reacting a Formula 15 compound with a mono-substituted hydrobrazine R7NH-NH2. The reaction takes place at a temperature of about 25 to about 100 ° C, and can take from about 1 hour to about 24 hours to complete.
[0073] [0073] A Formula 15 compound can in turn be prepared by reacting a Formula 16 compound with DMF DMA or Bredereck's reagent, optionally in the presence of a co-solvent such as DMF, at a temperature from about 50 to about 150 º. The reaction takes about 1 to about 24 hours to complete.
[0074] [0074] A Formula 16 compound can be prepared by treating a Formula 17 compound with a suitable acid (eg, p-toluenesulfonic acid, and the like) in a suitable inert solvent (eg, toluene, and the like). The reaction takes place at a temperature of about 50 to about 120ºC, and takes about 1 to about 24 hours to complete.
[0075] [0075] Finally, a compound of Formula 17 can be prepared by reacting 4-chloro-2- (methylthio) -pyrimidine with tert-butyl cyanoacetate in the presence of a suitable base (for example, hydride sodium and the like) and a suitable solvent (for example, DMSO and the like), at a temperature of about 25 to about 80 ° C. The reaction takes about 1 to about 24 hours to complete.
[0076] [0076] The Formula 11b compounds, which are a subset of the Formula 11 compounds in which M is a halogen, can be prepared by proceeding as in the following Reaction Scheme VI: Reaction Scheme VI o nm NC NH, me NA - AE - à À; (29) ea 27) À (25) À, Nº Roo o Re
[0077] [0077] A compound of Formula 20 can, in turn, be prepared
[0078] [0078] A Formula 22 compound can be prepared by reacting a Formula 23 compound with DMF DMA or Bredereck's reagent, optionally in the presence of a co-solvent such as DMF, at a temperature of about 50 ° C to about 50 ° C. of 150 º. The reaction takes about 1 to about 24 hours to complete.
[0079] [0079] A Formula 23 compound in which R50 is chlorine, bromine, or iodine can be prepared by reacting a Formula 24 amine compound with a suitable reagent diazotization system (for example, nitrous acid together with a copper (1) salt halide, sodium nitrite, together with p-toluenesulfonic acid and potassium iodide, or isoamylnitride together with boron-THF trifluoride, iodine, potassium iodide , and acetonitrile). The reaction takes place at a temperature of about 0 to about 80ºC, and takes about 1 to about 6 hours to complete.
[0080] [0080] A Formula 24 compound can in turn be prepared by reacting a Formula 25 compound with an organometallic reagent such as methyl lithium, bromine methyl lithium complex, or a reagent of methylmagnesium halide, in an inert solvent such as THF, ether, or cyclopropyl methyl ether, at a temperature of about 0 to about 100 ° C, followed by treatment with an aqueous extinguishing solution. The reaction takes about 2 to about 48 hours to complete.
[0081] [0081] A Formula 25 compound can be prepared by reacting a Formula 26 compound with a Formula 3 compound, as described for the Reaction Scheme | Alternatively, a Formula 25 compound can be prepared from a Formula 27 compound, in which the two groups R ", taken together form an acid-labile protecting group (for example, an imine such as benzylidene or a carbamate, such as t-butylcarbamate). The reaction is carried out by treating a compound of Formula 27 with an aqueous acid reagent (for example, concentrated hydrochloric acid and the like) in a solvent such as ethanol, at a temperature of about 25 to about 100 ° C. Preferably, the two groups R "together form an imine such as benzylidine.
[0082] [0082] A compound of Formula 27 can in turn be prepared by reacting a compound of Formula 28 with a compound of Formula 29, in which the two groups R ", taken together form a protecting group labile acid (for example, such an imine as benzylidene or a carbamate, such as t-butylcarbamate). The reaction is carried out in a solvent (for example, toluene, methanol, or ethanol) at a temperature of about 25 to about 120ºC, optionally in the presence of a catalyst, such as DMAP, and takes about 1 to about 24 hours to complete, optionally, the reaction is carried out in an inert solvent (for example, THF and the like) in the presence of a base (for example n-butyl lithium and the like), at a temperature of about -80 to about 25 ° C, for a time of about 0.5 to about 12 hours.
[0083] [0083] A compound of Formula 29 can be prepared by methods known to those skilled in the art. For example, a compound of Formula 29, in which the two groups R ", taken together form a benzylidene group, can be prepared by reacting benzaldehyde with a mono-substituted hydrazine
[0084] [0084] The compounds of Formula 8 or Formula 8a can be prepared as described in the following Reaction Scheme VII: Reaction Scheme VII R3 Rs By MM RR M Rs oo RO R $ O (51) (50) (8) Ra Roo Ba, / X NV AQ no Ro -B Rs M RR R'O AR: (50a) (8a) where R2, R3, R4, R5, and Y are as defined in the Summary of the Invention, M is a group (eg, iodine, bromine, chlorine, trifluoromethanesulfonyloxy, and the like), and each R 'can be, for example hydrogen, methyl, and the like, or the two R' groups can be joined to form an ester of cyclic boronate. The two R90 groups can each be hydrogen, or the two R90 groups, taken together, can represent a suitable nitrogen protecting group (for example, one R90 can be hydrogen and the other can be BOC). Formula 8 or Formula 8a compounds can be prepared by reacting a Formula 50 or Formula 504 compound, respectively, with a diboro compound (for example, bis diboro chloride (pinacolate) and the like) in the presence of a suitable transition metal catalyst (for example PdCl2 (dppf)), and a suitable base (for example, potassium acetate and the like) in a suitable solvent (for example, toluene, dioxane and the like). The reaction proceeds over a temperature range of about 20 ° C to about 120 ° C and can take up to about 24 hours to complete. A Formula 50 compound can, in turn, be prepared by sulfonylating a Formula 51 compound, as described for Reaction Scheme | l. It will be appreciated by a person skilled in the art that compounds of Formula 51 or formula 50a, for example, 3-bromoanilines, or N-BOC-protected 3-bromoanilines, can be prepared by a variety of methods, including, but not limited to a, those described in the Examples below.
[0085] [0085] A compound of Formula 70 can be prepared as described in the following Reaction Scheme VIII: Reaction Scheme VIII Foo TAA—, Re the FF (74) “(73)
[0086] [0086] A Formula 71 compound can in turn be prepared by a two-step process consisting of converting the hydroxy group of a Formula 73 compound to a suitable leaving group, followed by displacement with an azide anion . For the first step, suitable reagents include phosphorus tribromide, or methanesulfonyl chloride in combination with a suitable base such as triethylamine. The reactions are carried out in a suitable solvent (for example, dichloromethane, and the like), at a temperature of about 0 to about 50 ° C. For a second step, the displacement is carried out with an azide reagent (for example, sodium azide, and the like) in a suitable solvent (for example, DMF or DMSO) at a temperature from about 25 to about 150 ºC . The reaction takes about 1 to about 24 hours to complete. Alternatively, the transformation can be carried out in one step, by treating a compound of Formula 73 with a phosphine reagent (eg, triphenylphosphine, and the like) and a dazodicarboxylate reagent (eg, diethylazodicarboxylate and the like) in presence of hydrazóico acid (formed in situ from an azide salt, such as sodium azide, and an acid). The reaction takes place at a temperature of about -80 ° C to about 75 ° C, and takes about 1 to about 24 hours to complete.
[0087] [0087] A Formula 73 compound can be prepared by treating a Formula 74 compound with a chloroform compound (e.g., methyl chloroform compound and the like) or an alternative alkoxycarbonylation reagent, such as di-tert-butyldicarboxylate. The reaction takes place in an inert solvent (for example, dichloromethane and the like), at a temperature of about -80 to about 25 ° C, and takes about 1 to about 12 hours to complete. A base such as triethylamine can optionally be used. The reaction can also be carried out in a two-phase system consisting of a solvent such as THF or dioxane, and an aqueous base solution, such as aqueous sodium bicarbonate solution, at a temperature of about
[0088] [0088] A compound of formula 70 can also be prepared as described in the following Reaction Scheme IX: Reaction Scheme IX HAN -R56 Pro -. Ç "—— (77) (76) H o. 8 RN and Ra Y ON O Rss ss (75) (70) in which R8b is as defined in the Summary of the Invention, R55 is selected from a C1- 4alkyl or -C1-4alkyls substituted by halo, and R56 is a suitable protecting group, for example benzyloxycarbonyl (CBz) .A compound of Formula 70 can be prepared by deprotecting a compound of Formula 75. For example, one with - Formula 70 station can be prepared by treating a Formula 75 compound, where R56 is Cbz, with a suitable reduction system (for example, hydrogenation over a palladium catalyst, and the like) in a suitable solvent ( for example, methanol, ethanol, MTBE, or ethyl acetate) at a temperature of about 25 to about 75 ° C, optionally in the presence of an acid such as hydrogen chloride, over a period of about 0, 5 to about 12 hours Alternatively, deprotection can be performed under transfer hydrogenation conditions, using a hydrogen donor appropriate ion, such as formic acid, ammonium formate, or 1,4 cyclohexadiene. A Formula 75 compound can in turn be prepared by reacting a Formula 76 compound with a chloroform compound (for example, methyl chloroform compound and the like) or an alternative alkoxycarbonylation reagent, such as di-tert-butyldicarboxylate . The reaction takes place in an inert solvent (for example, dichloromethane and the like), at a temperature of about -
[0089] [0089] It will be appreciated by a person skilled in the art that a Formula 70 compound can be either a single enantiomer or a mixture of enantiomers, and that a single Formula 70 enantiomer compound can be obtained by starting with an appropriate single enantiomer compound. Formula 74 or Formula 77.
[0090] [0090] Detailed examples for the synthesis of a compound of Formula la can be found in the Examples, below. Additional processes for the production of compounds of the Invention
[0091] [0091] A compound of the present invention can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable organic or inorganic acid. Alternatively, a pharmaceutically acceptable base addition salt of a compound of the present invention can be prepared by reacting the free acid form of the compound with a pharmaceutically acceptable organic or inorganic base.
[0092] Alternatively, the salt forms of the compounds of the present invention can be prepared using salts of the starting materials or intermediates.
[0093] [0093] The free acid or free base forms of the compounds of the present invention can be prepared from the corresponding base addition salt or acid addition salt from, respectively. For example, a compound of the present invention in an acid addition salt form can be converted to the corresponding free base by treatment with a suitable base (for example, solution of damonium hydroxide, sodium hydroxide, and the like). res). A compound of the present invention in a base addition salt form can be converted to the corresponding free acid by treatment with a suitable acid (for example, hydrochloric acid, etc.)
[0094] [0094] The compounds of the present invention in unoxidized form can be prepared from N-oxides of compounds of the present invention by treatment with a reducing agent (for example, sulfur dioxide, sulfur, triphenyl phosphine, boron -lithium hydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (eg acetonitrile, ethanol, aqueous dioxane, or similar), at 0 ° C to 80 ° C.
[0095] [0095] Prodrug derivatives of the compounds of the present invention can be prepared by methods known to those skilled in the art (for example, for more details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, vol. 4, p. 1985). For example, suitable prodrugs can be prepared by reacting a non-derivatized compound of the present invention with a suitable carbamylating agent (for example, 1,1-acyloxyalkylcarbonochloridate, para-nitrophenyl carbonate, or the like) .
[0096] [0096] The protected derivatives of the compounds of the present invention can be made by means known to those skilled in the art. A detailed description of the techniques applicable to the creation of protective groups and their removal can be found in TW Greene, "Protecting Groups in Organic Chemistry", 3rd edition, John Wiley and Sons, Inc., 1999.
[0097] [0097] The compounds of the present invention can conveniently be prepared, or formed during the process of the present invention, as solvates (for example, hydrates). Hydrates of compounds of the present invention can be conveniently prepared by recrystallization from an aqueous / organic solvent mixture, using organic solvents such as dioxins, tetrahydrofuran or methanol.
[0098] [0098] The compounds of the present invention can be prepared as their individual esterisomers by reacting a racemic mixture of the compound with an optically resolving agent.
[0099] [0099] In summary, the compounds of Formula | can be done through a process, which involves: reaction schemes | IX, and optionally, the conversion of a compound of the present invention to a pharmaceutically acceptable salt thereof; optionally, converting a salt form of a compound of the present invention to a non-salt form; optionally, converting an unoxidized form of a compound of the present invention to a pharmaceutically acceptable N-oxide; optionally, converting an N-oxide form of a compound of the present invention to its unoxidized form;
[00100] [00100] Insofar as the production of the starting materials is not particularly described, the compounds are known or can be prepared analogously to methods known in the art or as described in the Examples below.
[00101] [00101] Those skilled in the art will appreciate that the above transformations are only representative of methods for the preparation of the compounds of the present invention, and that other well-known methods can also be used. EXAMPLES
[00102] [00102] The present invention is further exemplified, but not limited, by the following intermediates and the examples that illustrate the preparation of compounds of Formula | according to the present invention.
[00103] [00103] The abbreviations used are as follows: benzyloxycarbonyl (Cbz); tert-butoxycarbonyl (BOC); cell proliferation (CP); dichloromethane (DCM); N N-diisopropylethylamine (DIPEA); [1,1'-Bis (diphenylphosphino) ferrocene] dichloropalladium (ll) (PdCl2 (dppf)); 1,2-dimethoxyethane (DME); N, N-dimethyl acetamide (DMA); N .N-dimethylaminopyridine (DMAP); N, N-dimethyl formamide (DMF); N, N-dimethyl formamide dimethylacetal (DMF DMA); dimethyl sulfoxide (DMSO); ethyl acetate (EtOAc); high pressure liquid chromatography (HPLC); isopropyl acetate (iPrOAc); methanesulfonyl (Ms); 2-methyltetrahydrofuran (2-methylTHF); N-methylpyrolidi-
[00104] [00104] Intermediate. Cyano- (2-methylthio-pyrimidin-4-yl) -acetic acid tert-butyl ester ns aa THE
[00105] [00105] To a suspension of sodium hydride (7.15 g, 179 mmoles, 60% in oil) in DMSO (100 ml) was added tert-butyl cyanoacetate (24.8 g, 170 mmoles) at 23 ° C. After the evolution of hydrogen was finished, 4-chloro-2-methylthiopyrimidine (13.7 g, 85 mmol) was added. The reaction was heated to 80 ºC for 16 h. The reaction mixture was then cooled to room temperature and quenched with ice-cooled saturated ammonium chloride (300 mL). The solid was filtered and washed with water (2x200 mL). 300 mL of hexane was added to the solid and the suspension was heated to 60 ºC for 1 h and then cooled to room temperature. The solid was filtered and washed with hexane to yield the title compound; * H NMR 400 MHz (CDCl3) 5 7.82 (ad, 1H), 6.74 (ad, 1H), 2.63 (s, 3H), 2.61 (s, 1H), 1.52 (s, 9H); MS m / z:
[00106] [00106] To a solution of Cyano- (2-methylthio-pyrimidin-4-yl) -acetic acid tert-butyl ester intermediate (5.3 g, 20 mmol) in anhydrous toluene (100 mL) was added p-toluenesulfonic acid (800 mg). The mixture was heated to reflux for 8 h, cooled to room temperature and extracted with ethyl acetate. The organic layer was washed with 1N aqueous sodium hydroxide solution and brine, dried with sodium sulfate, filtered and concentrated. The crude product was purified
[00107] [00107] Step 1. 3- (Dimethylamino) -2- (2- (methylthio) pyrimidin-4-yl) acrylonitrile. N, N-Dimethylformamide dimethyl acetal (30 ml) was added to Intermediate (2-Methylthio-pyrimidin-4-yl) -acetonitrile (2.62 9, 15.7 mmols) and the mixture was heated at 100 ° C for 16 h. The cooled reaction mixture was concentrated, and the residue was used without further purification.
[00108] [00108] Step 2. 4- (2- (Methylthio) pyrimidin-4-yl) -1H-pyrazol-3-amine. To the mixture of crude 3- (dimethylamino) -2- (2- (methylthio) pyrimidin-4-yl) acrylonitrile from the previous step (total amount) and hydrazine monohydrate (2.36 mL, 47 mmol) in anhydrous ethanol (75 ml) was heated to 80 ºC for 16 hours. The reaction mixture was cooled to room temperature and concentrated. The reaction mixture was partitioned between ethyl acetate and brine. The organic layer was separated and washed with brine, dried over sodium sulfate, filtered and concentrated. The crude product was purified by silica gel chromatography (2 to 5% methanol in dichloromethane eluent) to yield 4- (2- (methylthio) pyrimidin-4-yl) - 1H-pyrazol-3-amine: * H NMR 400 MHz (DMSO-ds) 5 11.9 (s, 1H), 8.3 (s, 1H), 7.87 (s, 1H), 7.23 (s, br 1H), 6.43 (s, 1H), 5.74 (s, 1H), 2.53 (s, 3H); MS m / z: 208.0 (M + 1).
[00109] [00109] Intermediate. 1-Isopropyl-4- (2- (methylthio) pyrimidin-4-i1) -1H-pyrazol-3-amine:
[00110] [00110] Intermediate 4- (2- (Methylthio) pyrimidin-4-yl) -1H-pyrazol-3-amine (10.0 g, 40 mmol) was dissolved in THF (200 mL), followed by the addition of 2- iodopropane (6.3 ml, 63 mmols) and sodium methoxide (25% by weight of the solution in methanol, 14.3 ml, 63 mmols). The mixture was heated to 50ºC with stirring under a nitrogen atmosphere for 3 d, then it was concentrated in vacuo. The residue was taken up in ethyl acetate (200 mL) and washed with aqueous potassium carbonate solution and brine, then dried with sodium sulfate, filtered, and concentrated to provide the brown residue. The residue was chromatographed on silica gel (hexane / ethyl acetate eluent) to provide 1-isopropyl-4- (2- (methylthio) pyrimidin-4-yl) -1H-pyrazol-3-amine as a solid; * H NMR 400 MHz (CDCl3) 5 8.23 (d, J = 5.6 Hz, 1H),
[00111] [00111] Similarly prepared were: 1-Ethyl-4- (2- (methylthio) pyrimidin-4-yl) -1H-pyrazol-3-amine and 1-Methyl-4- (2- (methylthio) pyrimidin- 4-i1) -1H-pyrazol-3-amine. Intermediary. 4- (3-sludge-1-isopropyl-1H-pyrazol-4-i1) -2- (methylthio) pyrimidine: N = “A, do THE
[00112] [00112] A mixture of Intermediate 1-isopropyl-4- (2- (methylthio) pyrimidin-4-yl) -1H-pyrazol-3-amine (4.0 g, 16.0 mmolis), isopentyl nitride (13.2 g, 112 mmols ), and methylene iodide (30 mL) was heated to 100 ° C for 3 h. Removal of the volatiles in vacuo provided a dark residue, in which it was purified by silica gel chromatography (2: 1 hexane / ethyl acetate eluent) to yield the title compound as a solid; MS m / z: 361.1 (M + 1).
[00113] [00113] Similarly prepared were: 4- (3-sludge-1-ethyl-1H-pyrazol-4-i1) -2- (methylthio) pyrimidine; 4- (3-sludge-1-methyl-1H-pyrazol-4-i1) -2- (methylthio) pyrimidine; and 4- (3-iodo-1H-pyrazole | -4-i1) -2- (methylthio) pyrimidine. Intermediary. - 4- (3-sludge-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazol-4-i1) -2- (methylthio) pyrimidine. N = A. HERE CG
[00114] [00114] A solution of 4- (3-iodo-1H-pyrazol-4-yl) -2- (methylthio) pyrimidine (270 mg, 0.85 mmol) and p-toluenesulfonic monohydrate (32 mg, 0.17 mmol ) in 3,4-dihydro-2H-pyran (1 ml) was heated to 60 ºC for 5 h. The cooled mixture was diluted with ethyl acetate, and the mixture was washed with water and brine, then dried with sodium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel (10% ethyl acetate eluent in hexanes) to provide the title compound. MS (m / z): 402.7 (M + 1). Intermediary. 4- (3-sludge-1-isopropyl-1H-pyrazole | -4-i1) -2- (methylsulfonyl) pyrimidine: N = e, THE THE
[00115] [00115] To a solution of Intermediate 4- (3-iodo-1-isopropyl-1H-pyrazol-4-i1) -2- (methylthio) pyrimidine (4.51 g, 12.5 mmol) in dichloromethane (60 mL) to The ºC was added m-chloroperbenzoic acid (3.65 g, 77% purity, 16.3 mmolis). The mixture was stirred at 0 ºC under nitrogen for 3 h, then it was diluted with ethyl acetate and washed with aqueous potassium carbonate solution and brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated to provide - 4- (3-iodo-1-isopropyl-1H-pyrazol-4-i1) -2- (methylsulfonyl) pyrimidine as a solid . MS m / z: 393.0 (M + 1).
[00116] [00116] Similarly prepared were: 4- (3-sludge-1-ethyl-1H-pyrazol-4-i1) -2- (methylsulfonyl) pyrimidine; and 4- (3-sludge-1-methyl-1H-pyrazol-4-i1) -2- (methylsulfonyl) pyrimidine. 7 “NH
[00117] [00117] To a round bottom flask containing anhydrous sodium acetate (8.29, 0.1 mol) in 125 ml of 50% ethanol was added isopropylhydrazine HCI salt (11.1 g, 0.1 mole) and benzaldehyde (10.6 g, 0.1 mol). The mixture was stirred at room temperature for 20 h. The reaction was extracted with ether (3 x 250 ml). The organic layers were combined and washed with aqueous sodium bicarbonate solution and brine and dried over sodium sulfate. Filtration, concentration, and co-evaporation with toluene (3x) provided the title compound as an oil. MS m / z 163.3 (M + 1).
[00118] [00118] Similarly prepared were: 1-Benzylidene-2-ethylhydrazine starting from ethylhydrazine oxalate, using methanol and triethylamine instead of ethanol and sodium acetate, respectively; and 1- Benzylidene-2-methylhydrazine starting from methylhydrazine, using methanol as solvent. Intermediary. 2 - ((2-Benzylidene-1-isopropylhydrazinyl) methylene) -malono-nitrile:
[00119] [00119] A solution of Intermediate 1-benzylidene-2-isopropyl-
[00120] [00120] To a solution of 2- (ethoxymethylene) malononitrile (15.2 9,
[00121] [00121] Similarly prepared was 2 - ((2-Benzylidene-1-methylhydrazine)
[00122] [00122] A mixture of Intermediate 2 - ((2-benzylidene-1-isopropylpyridin-zinyl) -methylene) malononitrile (9.42 g, 40 mmols), concentrated hydrochloric acid (5 ml), and ethanol (50 ml ) was heated to reflux per min. The reaction mixture was concentrated and ether (50 ml) was added. The mixture was sonified, then the upper ether layer was discarded. To the residue, 20 ml of 5N aqueous sodium hydroxide solution were added and the mixture was extracted with dichloromethane (3x). The organic layers were combined, dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (1: 1 hexane / ethyl acetate eluent) to yield 3-amino-1-isopropyl-1H-pyrazole-4-carbonitrile as a brown solid. * H NMR (400 MHz, DMSO-ds) 5
[00123] Similarly prepared were: 3-amino-1-ethyl-1H-pyrazole-4-carbonitrile; and 3-amino-1-methyl-1H-pyrazole-4-carbonitrile. Intermediary. 1- (3-Amino-1-isopropyl-1H-pyrazol-4-yl) ethanone NH, À,
[00124] [00124] To a solution of Intermediate 3-amino-1-isopropyl-1H-pyrazole-4-carbonitrile (5.29 g, 36.5 mmols) in anhydrous THF at 200 ml at 0 ° C was added methylmagnesium bromide solution (3 M in ether ,
[00125] [00125] Similarly prepared were: 1- (3-Amino-1-ethyl-1H-pyrazol-4-yl) ethanone; and 1- (3-Amino-1-methyl-1H-pyrazol-4-yl) ethanone.
[00126] [00126] Intermediate. 1- (3-sludge-1-isopropyl-1H-pyrazol-4-yl) ethanone! THE
[00127] [00127] To a solution of Intermediate 1- (3-amino-1-isopropyl-1H-pyrazol-4-yl) ethanone (3.97 g, 24 mmols) and p-TsOH.H2O (9.07 g, 48 mmols, 2 eq ) in 150 ml of acetonitrile at 0 ºC was added dropwise the solution of sodium nitride (2.97 g, 43 mmols, 1.8 eq) and potassium iodide (8.0 g, 48 mmols, 2.0 eq) in 20 ml water. The mixture was stirred at this temperature for 10 minutes and then allowed to cool to room temperature and stirred for 3 h. The mixture was concentrated and then diluted with water and neutralized with aqueous sodium carbonate solution at pH 9 to 10. The mixture was extracted with ethyl acetate (3x). The organic layers were washed with sodium thiosulfate solution, dried with sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (1: 1 hexanes / ethyl acetate eluent) to provide the title compound as a light brown solid. * H NMR (400 MHz, DMSO-ds) 5 8.51 (s, 1H), 4.53 (m, 1H), 2.37 (s, 3H), 1.41
[00128] [00128] Similarly prepared were: 1- (3-sludge-1-ethyl-1H-pyrazol-4-yl) ethanone; and 1- (3-sludge-1-methyl-1H-pyrazol-4-yl) ethanone. Intermediary. 3- (Dimethylamino) -1- (3-iodo-1-isopropyl-1H-pyrazol | -4-yl) prop-2-en-1-one: Ms, x
[00129] [00129] A mixture of Intermediate 1- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) ethanone (5.0 g, 18.0 mmol) and N, N-dimethylformamide dimethyl acetal (50 mL) was heated to 155 ° C for 20 h. The mixture was concentrated in vacuo to provide the crude title compound. MS m / z 334.0 (M +1).
[00130] [00130] Similarly prepared were: 3- (Dimethylamino) -1- (3-iodo-1-ethyl-1H-pyrazol-4-yl) prop-2-en-1-o; and 3- (Dimethylamino) -1- (3-iodo-1-methyl-1H-pyrazol-4-yl) prop-2-en-1-one. Intermediary. 4- (3-sludge-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-amine N = Ad / à THE
[00131] [00131] A mixture of Intermediate 3- (dimethylamino) -1- (3-iodine-1-that-propyl-1H-pyrazol-4-yl) prop-2-en-1-one crude (4.0 g, 12.0 millis ), guanidine hydrochloride (2.63 g, 27.6 mmols), lithium hydroxide (635 mg, 27.6 mmols), and sec-butanol (50 ml) was heated with stirring in reaction and sealed at 110 ºC for 20 h. The cooled reaction mixture was concentrated, then water was added and the mixture was extracted with ethyl acetate. The combined extracts were dried with sodium sulfate, filtered, and concentrated. Ethyl acetate was added to the solid residue and the mixture was sonicated. The solid product was
[00132] Similarly prepared were: 4- (3-sludge-1-ethyl-1H-pyrazol-4-yl) pyrimidin-2-amine; and 4- (3-sludge-1-methyl-1H-pyrazol-4-yl) pyrimidin-2-amine. Intermediary. 4- (3-sludge-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ol N = AN / | " THE
[00133] [00133] Sodium nitride (314 mg, 4.55 mmol) was added portionwise to a stirred mixture of Intermediate 4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-amine (500 mg , 1.52 mmol) and trifluoroacetic acid (15 ml) at 0ºC. The mixture was allowed to cool to room temperature and was stirred for 1 h, then the solvent was removed in vacuo. The crude mixture was diluted with ethyl acetate and washed with saturated aqueous potassium carbonate solution and brine to provide the title compound as a solid. MS m / z 331.0 (M + 1).
[00134] Similarly prepared were: 4- (3-sludge-1-ethyl-1H-pyrazol-4-yl) pyrimidin-2-ol; and 4- (3-sludge-1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ol. Intermediary. 2-Chlorine-4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidine N = e, dq THE THE
[00135] [00135] A solution of Intermediate 4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-01 (438 mg, 1.33 mmol) in phosphorous oxychloride (10 ml) was heated to 110 ° C for 16 h. The mixture was concentrated in vacuo, then aqueous sodium bicarbonate solution was carefully added and the mixture was extracted with ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered, and concentrated to provide the title compound as a yellow solid. MS m / z 349.0 (M + 1).
[00136] Similarly prepared were: 2-Chloro-4- (3-iodo-1-ethyl-1H-pyrazol-4-yl) pyrimidine; and 2-Chloro-4- (3-iodo-1-methyl-1H-pyrazol-4-yl) pyrimidine. Intermediary. (S) -methyl oo 1-hydroxypropan-2-ylcarbamate: o Is
[00137] [00137] To a solution of (S) -alaninol (10 g, 130 mmol) and sodium bicarbonate (32.8 g, 390 mmol) in THF-H2O (1: 1, 650 mL) at 0 ° C was added dropwise dropwise methyl chloroform (11.4 mL, 143 mmol). The mixture was stirred and allowed to cool to room temperature for 4 h, and was then extracted with ethyl acetate. The organic layer was washed with 1N aqueous sodium hydroxide solution and brine, and was then dried over sodium sulfate, filtered and concentrated to yield the crude title compound, in which it was used without further purification. MS m / z 134.1 (M + 1).
[00138] [00138] Similarly prepared were: (R) -methyl 1-hydroxypropan-2-ylcarbamate, using (R) -alinol instead of (S) -alaninol; and (S) -1,1-Dimethylethyl 1-hydroxypropan-2-ylcarbamate using di-t-butyl-dicarbonate instead of methyl chloroformioate. Intermediary. (S) -Methyl 1-azidopropan-2-ylcarbamate: eta, the É
[00139] [00139] To a solution of Intermediate 1-hydroxypropan-2-ylcarbamate of (S) -methyl (2.65 g, 20 mmols) and triethylamine (7.0 ml, 50 mmols) in anhydrous dichloromethane (100 ml) methanesulfonyl (1.91 mL, 23.9 mmols). The mixture was stirred at room temperature for 3 h and was then extracted with ethyl acetate. The organic layer was washed with 1N sodium hydroxide solution and brine, and was then dried over sodium sulfate, filtered and concentrated. The crude mesylate product was then dissolved in dry DMF (70 ml) and sodium azide (5.2 g, 80 mmols) was added. The mixture was heated with stirring at 80 ҼC for 2 h. The cooled reaction mixture was concentrated and the residue was partitioned between ethyl acetate and brine. The organic layer was separated and washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel chromatography (8: 1 hexane / ethyl acetate eluent) to yield (S) - methyl 1-azidopropan-2-ylcarbamate. MS m / z 159.1 (M + 1).
[00140] [00140] Similarly prepared were: (R) -Methyl 1-azidopropan-2-ylcarbamate; and (S) -1,1-dimethylethyl 1-azidopropan-2-ylcarbamate. Intermediary. (S) -Methyl 1-aminopropan-2-ylcarbamate
[00141] [00141] To a solution of Intermediate 1-azidopropan-2-ylcarbamate of (S) -methyl (2.86 g, 18.2 mmols) in ethyl acetate (200 ml) was added 10% palladium on carbon (wet, 286 mg). The flask was degassed and refilled with hydrogen gas (flask, 1 atmosphere), and the mixture was stirred at room temperature for 16 hours. The reaction mixture was filtered through a pad of celite and washed with ethyl acetate. The filtrate was concentrated to provide crude (S) -methyl 1-aminopropan-2-ylcarbamate, where it was used without further purification. * 'H NMR 400 MHz (CDCl3) 5 4.79 (s, 1H),
[00142] [00142] Similarly prepared were: (R) -Methyl 1-aminopropan-2-ylcarbamate; and (S) -1,1-dimethyl-1-aminopropan-2-ylcarbamate
[00143] [00143] Intermediate. 1- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate of (S) -Methyl: mM) | Pla, AA
[00144] [00144] A solution of Intermediate 2-chloro-4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidine (1.4 9, 4.01 mmolis), 1-aminopropan-2-ylcarbamate ( S) -methyl (0.8 g, 6 mmols) and triethylamine (2.8 ml, 20 mmolis) in isopropanol (30 ml) and dioxane (20 ml) was heated in a sealed vessel at 125 ºC for 48 hours. The cooled mixture was concentrated in vacuo, and aqueous sodium bicarbonate was added to the residue. The mixture was extracted with ethyl acetate, and the combined extracts were dried over sodium sulfate, filtered, and concentrated. The crude residue was purified by silica gel column chromatography (1: 2 hexanes / ethyl acetate eluent) to provide the title compound as a white solid. MS m / z 445.0 (M + 1).
[00145] [00145] Similarly prepared were: 1- (4-) (R) -Methyl 1- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate; (S) -tert-butyl 1- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate; 3- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propanenitrile; 4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -N-methylpyrimidin-2-amine; and N '- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-yl) -N º No. -dimethylethane-1,2-diamine. Intermediary. N- (3-bromo-2 4-difluorfenyl) propane-1-sulfone-mida F. so wo F
[00146] [00146] A solution of 3-bromo-2,4-difluoraniline (4.16 g, 20 mmols, EP184384), n-propanesulfonyl chloride (4.6 ml, 40 mmolis),
[00147] [00147] A solution of 2-amino-3-fluorpyridine (1.0 g, 8.9 mmolis) in anhydrous THF (40 ml) was treated dropwise at -78ºC with n-butyllithium (1.6 M in hexanes, 13.9 ml, 22.3 mmols). Following the addition, the mixture was stirred at -78 ºC for 1 h, then the iodine solution (10.2 g,
[00148] [00148] Similarly prepared was: 3-chloro-4-iodopyridin-2-amine. Intermediary. 3-Bromo-2,5,6-trifluoraniline
[00149] [00149] To a microwave tube was added 1-bromo-2,3,4,5-tetrafluorbenzene (1.0 g) and 28% aqueous ammonium hydroxide (5 ml). The mixture was heated under microwave irradiation at 150 ºC for 2 hrs, then the mixture was poured into water and extracted with
[00150] [00150] A mixture of 2,5-dichloroaniline (0.2 g), N-bromosuccinimide (0.48 g) and THF (20 ml) was stirred at room temperature for 2 hrs. The solvent was removed, and the residue was purified by silica gel flash chromatography (8: 2 hexanes eluent / ethyl acetate) to yield the title compound. MS m / z: 318 (M + H) *.
[00151] [00151] Intermediate. 1,3-Dibromo-2,5-dichlorobenzene was] O. was]
[00152] [00152] A stirred mixture of 2,4-dibromo-3,6-dichloroaniline (5.0 g), tert-Butyl nitride (3.3 g) and EtOH (50 mL) was heated in a sealed tube at 50 ° C for 2 hrs . The mixture was concentrated and the residue was purified by silica gel flash chromatography (hexanes eluent) to yield the title compound. MS m / z: 303 (M + H) *.
[00153] [00153] Intermediate. 3-Bromo-2-chloro-5-fluoraniline
[00154] [00154] Step 1. 3-bromo-2-chloro-N- (diphenylmethylene) -5-fluoraniline. The mixture of 2,6-dibromo-4-fluor-1-chlorobenzene (865 mg, 3 mmol), benzophenone imine (0.61 ml, 3.6 mmol), Pd2 (dba); s (137 mg, 0.15 mmol), t- sodium butoxide (432 mg, 4.5 mmols), (S) -BINAP (280 mg,
[00155] [00155] Step 2. 3-Bromo-2-chloro-S5-fluoraniline. The solution of 3-bromo-2-chloro-N- (diphenylmethylene) -5-fluoraniline (1.16 g) in THF (20 ml) was treated with 2N hydrochloric acid (1.5 ml, 1 eq) and the mixture was stirred at room temperature for 2 h. The mixture was extracted with ethyl acetate and the combined organic layer washed with brine. The organic layer was dried over sodium sulfate and concentrated. The crude residue was chromatographed on silica gel (40: 1 to 15: 1 hexanes / ethyl acetate eluent) to provide the title compound, contaminated with benzophenone. MS m / z 223.9 (M + 1).
[00156] [00156] Similarly prepared were: 3-bromo-2,5-dichloroaniline; 3-bromo-2-chloro-5-methylaniline; and 3-bromo-2,5-difluoraniline.
[00157] [00157] A solution of 2-bromo-4-chloro-1-fluorbenzene (4.31 g, 20 mmols) was added dropwise at -78ºC solution of LDA in THF (prepared from diisopropylamine (3.38 ml, 24 mmols) ) and n-BuLi (1.6 M, 13.1 ml, 21 mmols)). The mixture was stirred at -78ºC for 1h, and then it was transferred slowly (- 30-60 min) through a cannula to a stirred mixture at -78ºC mixture of dry ice and THF (40 ml). The mixture was stirred at -78ºC for 1 h, and then it was allowed to cool to room temperature (evolution of gas). The mixture was concentrated, and was then treated with 50 ml of 1 N sodium hydroxide solution. The mixture was extracted with ethyl acetate (discarded). The aqueous layer was acidified with 1N hydrochloric acid, and then it was extracted with chloroform (3 x 400 ml). The chloroform extract was dried over sodium sulfate, filtered, and concentrated to provide the crude title compound. The product was contaminated with a small amount of the 2-bromo-6-chloro-3-flurobenzoic acid isomeric product. * H NMR per 3-Bromo-5-chloro-2-fluorobenzoic acid title compound: (400 MHz, CDCl3) 5 7.93 (dd, 1H, J = 2.8, 5.6 Hz), 7.79 (dd, 1H, J = 2.8, 5.6 Hz) ppm.
[00158] [00158] Similarly prepared were: 3-bromo-2,6-difluoro-benzoic acid; and 3-bromo-2-fluoro-5-methylbenzoic acid. Intermediary. Terc-butyl Cc A eu 3-bromo-5-chloro-2-fluorophenylcarbamate F
[00159] [00159] “A solution of Crude Intermediate 3-bromo-5-chloro-2-fluorbenzoic acid (2.03 g, 8 mmols), diphenylphosphoryl azide (2.07 mL,
[00160] [00160] Similarly prepared were: 3-bromo-2,6-difluorfenylcar-
[00161] [00161] A solution of tert-butyl 3-bromo-5-chloro-2-fluorophenylcarbamate (900 mg, 2.78 mmol) in DCM / TFA (1: 1, 20 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated, then the residue was taken up in ethyl acetate and washed with aqueous sodium bicarbonate and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated to provide the crude title compound (736 mg). MS m / z 223.9 (M + 1). Intermediary. 5-bromo-3-methoxy-2-methylaniline: d / AD HAN
[00162] [00162] “A reaction of the heterogeneous mixture of 4-bromo-2-methoxy-6-nitrotoluene (500 mg, 2,032 mmol), acetic acid (20 ml), and iron (1135 mg, 20.32 mmols) was stirred at room temperature for 24 hr. Ethyl acetate was added, then the mixture was filtered through celite and the filtrate concentrated. The residue was divided between ethyl acetate and the saturated aqueous sodium bicarbonate solution. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with water and brine, then dried over sodium sulfate, filtered and concentrated to yield the title compound. MS m / z: 218.0 (M + H) *. Intermediary. 5-chloro-2-fluorine-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- Terc-butyl phenylcarbamate:
[00163] [00163] A mixture of tert-butyl Intermediate 3-bromo-S-chloro-2-fluorophenylcarbonate (1.45 g, 4.46 mmols), bis (pinacolato) dibonon (1.79, 6.69 mmoles), acetate potassium (1.53g, 15.6 mmolis), PdCl2 (dppf) -CH2Cl2 (163 mg, 0.22 mmol), and dioxane (100 ml) was heated in a sealed tube at 100 ºC for 16 h. The crude mixture reaction was taken in ethyl acetate and washed with aqueous sodium bicarbonate solution and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated. The compound crude compound was diluted with hot hexane (600 mL), heated to 65 ºC for 30 min. then cooled to room temperature. The brown mixture was filtered through Celite and the filtered cake was washed with hexanes. The combined filtrates were concentrated to yield the crude title compound as a yellow oil. MS m / z 233 (M-pinacol-fBu).
[00164] [00164] Similarly prepared were: 5-chloro-2-fluorine-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline; 2,6-difluoro-3- (4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl) tert-butyl phenylcarbamate; N- (2,4-difluoro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) | oropane-1-sulphonamide; 2- (2-fluorine-3-nitrophenyl) -4,4,5,5-tetramethyl-1,3,2-dioxaborolane; 2,5-diflúor-3- (4,4,5,5-tetra-methyl-1,3,2-dioxaborolan-2-yl) aniline; 2-chloro-5-fluoro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline; 2,5-dichloro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaboro-lan-2-yl) aniline; 2-chloro-5-methyl-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline; Tert-butyl 2-fluorine-5-methyl-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenylcarb-matte; 3-fluorine-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridin-2-amine; 2,3,6-trifluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline; 3-chloro-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridin-2-amine; 3-chloro-5-
[00165] [00165] The mixture of Intermediate 2- (2-fluor-3-nitrophenyl) -4,4,5,5-tetramethyl-1,3,2-dioxaborolane (500 mg), 10% palladium on carbon (50 mg ) and ethyl acetate (20 ml) was stirred under 1 hydrogen atmosphere for 16 h. The mixture was sparged with nitrogen and filtered. The filtrate was concentrated to provide the title compound, in which it was used without further purification. MS m / z 237.1 (M + 1). Example 1 N - [(28) -1 - [(4-13- [2,6-difluoro-3- (propane-1-sulfonamido) phenyl] -1- (propan-2-i1) -1H-pyrazole- 4-yl) pyrimidin-2-i) methyl] propan-2-yl] methyl carbamate (Compound 7 in table 1) N = F poa oe MeO, CHN / * F THE
[00166] [00166] A mixture of Crude Intermediate N- (2,4-difluoro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) | oropane-1-sulfonamide (854 mg), Intermediate 1- (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate (350 mg, 90 % pure), tetra-queso (triphenylphosphine) palladium (0) (90 mg), 2 M aqueous sodium carbonate solution (6 ml), toluene (50 ml), and ethanol (6 ml) was heated to 80 ° C for 16 h. The cooled mixture was extracted with ethyl acetate and the combined organic extracts were washed with brine. The organic phase was dried over sodium sulfate and concentrated. The crude product was purified by silica gel chromatography (70: 1 to 40: 1 DCM / methanol eluent) to provide the title compound. Example 2 N - [(28) -1- (f4- [3- (2-chloro-5-fluor-3-methanesulfonamidophenyl) -1- (propan-2-i1) -1H-pyrazol-4-yl] pyrimidin -2-ylamino) propan-2-yl | methyl carbamate (Compound 15 in table 1)
[00167] [00167] Step 1. 1- (4- (3- (3-amino-2-chloro-5-fluorophenyl) -1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2- (S) -Methyl ilcarbamate. The mixture of Crude Intermediate 2-chloro-5-fluor-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline (214 mg), Intermediate 1- (4- (S) -methyl (S) -methyl (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino (68 mg, 0.14 mmol), tetrakis (triphenylphosphine) -paladium (0 ) (16 mg), 2 M aqueous sodium carbonate solution (3 ml), toluene (18 ml), and ethanol (3 ml) was heated to 85 ºC for 16 h. The mixture was extracted with ethyl acetate and the combined organic extracts were washed with brine. The organic phase was dried over sodium sulfate and concentrated. The crude product was purified by silica gel chromatography (60: 1 to 40: 1 DCM / methanol eluent) to provide the title compound (46 mg) contaminated with 1- (4- (1- (S) -methyl isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate. MS m / z 462.1 (M +1).
[00168] [00168] Step 2. 1- (4- (3- (2-chloro-5-fluoro-3- (methanesulfonamido) phenyl) -1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan (S) -Methyl -2-ylcarbamate. The mixture of the aniline product from step 1 (46 mg), pyridine (2 ml), triethylamine (1 ml), DCM (4 ml), and methanesulfonyl chloride (23 ul, 0.3 mmol) was stirred at room temperature for 16 h. The crude mixture reaction was concentrated, then the residue was taken up in a mixture of toluene (9 ml), ethanol (1 ml), sodium carbonate (2 g), and water (10 ml). The stirred mixture was heated to 85 ºC for 16 h. The run through Step 1 provided the crude product, in which it was purified by silica gel chromatography (60: 1 to 40: 1 DCM / methanol eluent) to provide the title compound. Example 3 N - [(28) -1 - [(4- (3- [5-chloro-2-fluorine-3- (propane-1-sulfonamido) phenyl] -1- (pro- pan-2-yl) -1H-pyrazol-4-ylYpirimidin-2-yl) amino] propan-2-yl | methyl carbamate (Compound 1 in table 1) Cl ENS NHSO, Pr Messe EN F THE
[00169] [00169] Step 1. 1- (4- (3- (5-chloro-2-fluoro-3- (tert-butoxycarbonylamino) phenyl) -1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2 -ylamino) propan-2-ylcarbamate of (S) -Methyl. The mixture of crude Intermediate 5-chloro-2-fluor-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) tert-butyl phenylcarbamate (2.0 g), Intermediate 1 - (S) Methyl (4- (3-iodo-1-isopropyl-1H-pyrazol | -4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate (600 mg, 1.34 mmol), tetrakis (triphenylphos) -fine) palladium (0) (150 mg, 0.13 mmol), 2 M aqueous sodium carbonate solution (6.7 ml, 13.5 mmol), toluene (80 ml), and ethanol (6 ml) was heated to 80 ° C for 16 h. The mixture was extracted with ethyl acetate and the combined organic extracts were washed with brine. The organic phase was dried over sodium sulfate and concentrated. The crude product was purified by silica gel chromatography (80: 1 to 60: 1 DCM / methanol eluent) to provide the title compound contaminated with triphenylphosphine oxide. MS m / z
[00170] [00170] Step 2. 1- (4- (3- (3-amino-5-chloro-2-fluorophenyl) -1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2- (S) -Methyl ilcarbamate.
[00171] [00171] Step 3. N - [(28) -1 - [(4- (3- [5-chloro-2-fluoro-3- (propane-1-sulfo-na-humid) phenyl] -1- ( propan-2-yl) -1H-pyrazol-4-yl) pyrimidin-2-yl) amino] propan -2-yl] methyl carbamate. The mixture of 1- (4- (3- (3-amino-5-chloro-2-fluorophenyl) -1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbamate S) -methyl (41 mg, 0.09 mmol), triethylamine (1 ml), and DCM (4 ml) was treated with propanesulfonyl chloride (40 mg, 0.27 mmol). The mixture was stirred at room temperature for 16 h. The crude mixture was concentrated, and the residue was taken up in a mixture of toluene (9 ml), ethanol (1 ml), sodium carbonate (2 g), and water (10 ml). The stirred mixture was heated to 85 ºC for 16 h. The run according to Step 1 provided the crude product, in which it was purified by silica gel chromatography (60: 1 to 40: 1 DCM / methanol eluent) to provide the title compound. Example 4 N - [(28) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) -1- (oxan-2-yl) -1H-pyrazol-4-yl] pyrimidin -2-ylYamino) propan-2-yl | methyl carbamate (Compound 33 in table 1) and N - [(28) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) -1H-pyrazol-4-yl] pyrimidin-2-ylYamino) propan-2-yl | methyl carbamate (Compound 31 in table 1)
[00172] [00172] Step 1. 5-Chloro-2-fluorine-3- (4- (2- (methylthio) pyrimidin-4-i1) -1- (tetrahi-dro-2H-pyran-2-yl) -1H- pyrazol-3-yl) aniline. Prepared according to the procedure of Example 3, step 1, starting from Intermediate 4- (3-iodo-1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazol-4-11) - 2- (methylthio) pyrimidine and Intermediate 5-chloro-2-fluoro-3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline. MS m / z 420.0 (M + 1).
[00173] [00173] Step 2. N- (5-Chloro-2-fluorine-3- (4- (2- (methylthio) pyrimidin-4-i1) -1- (tetrahydro-2H-pyran-2-yl) -1H -pyrazol-3-yl 'phenyl) methanesulfonamide) and N- (5-chloro-2-fluor-3- (4- (2- (methylthio) pyrimidin-4-yl) -1- (tetrahydro-2H-pyran- 2-yl) -1H-pyrazol-3-yl) phenyl) - N- (methylsulfonyl) methanesulfonamide. To a solution of 5-chloro-2-fluor-3- (4- (2- (methylthio) pyrimidin-4-yl) -1- (tetrahydro-2H-pyran-2-yl) -1H-pyrazol-3- il) aniline (233 mg, 0.55 mmol) and triethylamine (2 ml) in dichloromethane (10 ml) methanesulfonyl chloride (0.13 ml, 1.66 mmol) was added. The mixture was stirred at room temperature for 16 h, providing a mixture of the title compounds (LCMS analysis). Ethyl acetate was added and the mixture was washed with water and brine, then the organic layer was dried over sodium sulfate, filtered, and concentrated to provide the crude title mixture, in which it was used without further purification. MS m / z monosulfonamide 498.0 (M + 1); bis-sulfonamide 576.0 (M + 1)
[00174] [00174] Step 3. N - [(28) -1 - ((4- [3- (5-chloro-2-fluor-3-methanesulfone-phenyl) -1- (oxan-2-yl) - Methyl 1H-pyrazol-4-yl] pyrimidin-2-yl «<amino) propan-2-yl] carbamate The crude product mixture from Step 2 was dissolved in THF-H2O (1: 1, 30 mL ) and treated at room temperature with Oxone & (1.68 g, 2.75 mmols). The mixture was stirred at room temperature for 16 h, then ethyl acetate was added.
[00175] [00175] Step 4. N - [(28) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfone-midophenyl) -1H-pyrazol-4-yl] pyrimidin-2-yl «<amino) methyl propan-2-yl | carbamate. To a solution of (28S) -1- (4- (3- (5-chloro-2-fluorine-3- (methylsulfonamide) phenyl) -1- (tetrahydro-2H-pyran-2-yl) -1H -pyrazol-4-yl) pyrimidin-2-ylamino) propan-2-ylcarbate-methyl (94 mg, 0.16 mmol) in MeOH (15 ml) concentrated hydrochloric acid (0.5 ml) was added. The mixture was stirred at room temperature for 16 h. Aqueous sodium bicarbonate was added in order to adjust the pH to 9 and the mixture was extracted with ethyl acetate. The organic layer was washed with aqueous sodium bicarbonate and brine. The crude product was purified by silica gel chromatography (30: 1 to 15: 1 dichloromethane / methanol eluent) to provide the title compound. Example 5 N - [(28) -1- (f4- [3- (5-chloro-2-fluoro-3-methanesulfonamidophenyl) -1- (propan-2-i1) -1H-pyrazol-4-yl] pyrimidin -2-ylamino) propan-2-yl | methyl carbamate (Compound 9 in table 1) Cc! N = pa eme MeO, CHN and F THE
[00176] [00176] Methanesulfonyl chloride (0.277 mL, 3.57 mmols) was added to a solution of 1- (4- (3- (3-amino-S5-chloro-2-fluorophenyl) -1-isopropyl-1H -pyrazol-4-yl) pyrimidin-2-ylamino) (S) - methyl propan-2-ylcarbamate (550 mg, 1.2 mmol) in DCM (30 mL) and pyridine (10 mL) and the mixture was stirred at temperature room for 16 h. The aqueous sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate and washed with brine. The organic phase was dried over sodium sulfate and concentrated. The crude product was purified by silica gel chromatography (60: 1 to 40: 1 DOM / methanol) to provide the title compound. An alternative synthesis is described in Example 6, below.
[00177] [00177] The following were also isolated from the reaction mixture: N- [(28) -2- (f4- [3- (5-chloro-2-fluoro-3-methanesulfonamidophenyl) -1- (propan-2-yl ) -1H-pyrazol-4-yl] Jpirimidin-2-yl) yamino) propyl | methyl carbamate (Compound 32 in table 1); N- (3- [4- (2-aminopyrimidin-4-yl) -1- (propan-2-yl) - 1H-pyrazol-3-i1] -5-chloro-2-fluorophenyl »methanesulfonamide (Compound 30 in Table 1) Example 6 N - [(28) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) -1- (propan-2-i1) -1H-pyrazole-4 -yl] pyrimidin-2-ylYamino) propan-2-yl] methyl carbamate (Compound 9 in table 1) Cc! N = pa ee MeO, CHN DX F THE
[00178] [00178] Step 1. 1-benzylidene-2-isopropylhydrazine. In a reactor equipped with a mechanical stirrer, a thermometer and an addition funnel under a nitrogen purge were charged with isopropylhydrazine hydrogen chloride salt (712 g, 6.43 millis), sodium acetate (528 g, 6 , 43 ml), and 50% ethanol (4500 ml). The mixture was stirred at
[00179] [00179] Step 2.2 - ((2-benzylidene-1-isopropylhydrazinyl) methylene) malononitrile. For a flask equipped with a mechanical stirrer, a thermometer and an addition funnel under a nitrogen purge were loaded with (ethoxyethylidine) malononitrile (755 g, 6.18 moles), DMAP (150 9, 1.23 mol), and ethanol (6400 mL). The mixture was stirred to give a dark orange solution and an endotherm from 20ºC to 12ºC was observed. 1-benzylidene-2-isopropylhydrazine (1101 g, crude) was added slowly over 15 min to give an exotherm at 32 ° C and an orange suspension. The orange suspension was heated to 50 ° C and maintained at 50 ° C for 30 min to give a dark brown suspension. Ethanol (3200 mL) was added to the mixture and the mixture was cooled to 20 ° C and maintained at 20 ° C for 1 h. The slurry was filtered and the solid cake was washed with ethanol (3000 ml). The solid was collected and dried under vacuum at 40 ° C / 5 torr for 3 h to provide the title compound as a yellow solid. HPLC purity> 299%.
[00180] [00180] Step 3. 3-Amino-1-isopropyl-1H-pyrazol-4-carbonitrile. For a flask equipped with a mechanical stirrer, a thermometer, a condenser, and an addition funnel under a nitrogen purge were charged
[00181] [00181] Step 4. 1 - (3-Amino-1-isopropyl-1H-pyrazol-4-i1) -ethanone. For a flask equipped with a mechanical stirrer, thermometer, reflux condenser, heating / cooling capacity, addition funnel, and nitrogen inlet / outlet, it was charged with 3-amino-1-
[00182] [00182] Step 5.1 - (3-iodo-1-isopropyl-1H-pyrazol-4-i1) -ethanone. A flask equipped with a mechanical stirrer, a thermometer and an addition funnel under a nitrogen purge was charged with 1 - (3-amino-1-isopropyl-1H-pyrazol-4-yl) -ethanone (250.0 g, 1 , 49 mol) and acetonitrile (3725 ml). The mixture was cooled to -20ºC. BF3.THF (313.1 g, 2.23 moles) was added dropwise, maintaining the internal temperature. <- 10ºC. Isoamyl nitrite (227.5 g, 1.94 mol) was added dropwise,
[00183] [00183] Step 6. 3 - (dimethylamino) -1 - (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -prop-2-en-1-one. 1 - (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -ethanone (640 g, 2,380) was loaded into a flask equipped with a mechanical stirrer, a thermometer and an addition funnel mols) and DMF (6.4 L). The resulting orange solution was heated to 120ºC. Bredereck's reagent (598.6 g, 3.43 mol) was added in one portion. The addition caused the temperature of the tablet to drop to 114ºC and the solution became darker orange. The mixture was stirred at 120 ° C for 20 min. The mixture was cooled to room temperature and then concentrated to 5 mmHg at 60 ° C to give an oily residue. The residue was dissolved in iPrOAc (2400 mL) by heating to 74 ° C. The mixture was cooled to 35 ° C and stirred to obtain a slurry. Heptane (6000 mL) was added at 35 ° C to room temperature over 1 h. The mixture was cooled to -15 ° C and filtered and the solid was dried under vacuum at 40 ° C for 3 h to give the title compound as a solid. HPLC purity> 98%. Mp: 106-109 "ºC.
[00184] [00184] Step 7.4 - (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -pyrimidin-2-amine. For a flask equipped with a mechanical stirrer, a thermometer, a Dean-Stark trap and a condenser under nitrogen purge (E) -3-dimethylamino-1- (3-iodo-1-isopropyl- 1H-) were loaded pyrazol-4-yl) - prop-2-en-1-one (735 g, 2.2 moles), guanidine carbonate (596 g, 3.3 moles) and NMP (5200 ml). The mixture was heated to 130 ° C and maintained at 130 ° C for 5 h. (Note: any low-boiling fractions were collected by a Dean-Stark trap). The mixture was cooled to 80 ° C and 15% aqueous sodium chloride (7500 mL) was added to 80 ° C to 35 ° C over - 1 hour. The product started to precipitate approximately halfway through the addition of aqueous sodium chloride. The mixture was further cooled to room temperature and maintained for 30 min. The solid product was collected by filtration and dried under vacuum at 65 ° C for 16 h to give the title compound as a solid. HPLC purity> 99%. Mp: 167-169 ° C.
[00185] [00185] Step 8.4 - (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -pyrimidin-2-ol. A flask equipped with a mechanical stirrer and thermometer under nitrogen purge was charged with TFA (748.8 mL). 4 - (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -pyrimidin-2-amine (300 g, 0.91 mol) was added in portions as a solid, keeping the internal temperature below 30ºC using a cold water bath. The mixture was stirred at room temperature for 10 min to obtain a solution. The mixture was cooled to 20ºC and sodium nitrite (79.79, 1.27 mol) was added in portions during 5 h at 22-28ºC, with rapid stirring. (Note: a gas evolution was observed and there was a slight exotherm that was easily controlled using a cold water bath). DOM (12 L) was added and the mixture was heated to 27 ° C. Water (4400 mL) was added (Note: the evolution of gas at the beginning). Saturated solution of potassium carbonate (- 1500 mL) was added slowly to the mixture to basify to pH - 9.0 (Note: A large amount of gas was evolved). To the mixture, a solution of sodium bisulfite (32 g, 0.30 mol) in water (100 ml) was added. The mixture was stirred at 27ºC for 15 min and the pH was adjusted to - 9.0. The DCM layer was separated and concentrated under vacuum (200-100 mm Hg) with a 40 ° C temperature bath until the residual weight was - 2300 g (- 1750 mL). MTBE (1500 mL) was added to the residue at 20ºC. The mixture was stirred 10 min at 20 ° C and was then filtered. The solid was dried 16 hours at 30 ° C under vacuum (5 torr) to give the title compound as an off-white solid. HPLC purity> 99%. Mp: 216-218 ° C.
[00186] [00186] Step 9. 2-Chloro-4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidine. For a flask equipped with a stirrer, thermometer, condenser, addition funnel and nitrogen inlet / outlet, it was loaded with 4 - (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -pyrimidin-2- 0l (311 g, 942 mmols). For the solid, acetonitrile (2500 mL) was added at 20ºC. The mixture was stirred to give a suspension. To the suspension was added DI-PEA (246.2 ml, 1.41 mol), followed by DMF (218.8 ml, 2.83 mol). The resulting suspension was stirred for 5 min at 20 ° C. To the suspension, POCI3 (217 g, 1.41 mol) was added at 20 -40ºC to give an orange solution. The mixture was heated to 80 ° C and maintained at 80 ° C for 3 h. The mixture was cooled to 10ºC and a solution of ammonium hydroxide (622 mL of 28%) in deionized water (5550 mL) was added slowly over 1.5 h, keeping the temperature below 20ºC.
[00187] [00187] Step10.2- (methoxycarbonylamino) propylcarbamate of (S) - Benzyl. To a suspension of (S) -1,2-diaminopropane dihydrochloride (50g, 340 mmols) in dichloromethane (500 ml) was added potassium carbonate (1,190 mmol). The suspension was stirred and filtered to collect the filtrate. The filtrate was cooled to 0 ° C at 5 ° C and stirred while benzyl chloroformioate (51 ml, 357 mmols) was added dropwise. After the completion of the addition, the reaction mixture was stirred for 3 ha0Oab5C, and was then allowed to warm to room temperature and was stirred at room temperature overnight. To this mixture, triethylamine (71 ml, 510 mmol) was added dropwise and the mixture was cooled to 0 ° C at 5 ° C. Methyl chloroformioate (28 ml, 357 mmols) was added slowly to O at 5 ° C and the mixture was allowed to warm to room temperature and was stirred overnight. The mixture was poured into water. The organic volatiles were removed under vacuum. The resulting aqueous suspension was filtered to collect the solids, and the filtered cake was then washed with ethyl acetate to provide a white solid (65 g, 92 to 94% HPLC purity). Multiple recrystallizations from ethyl acetate provided the title compound as a white solid, 99.5% HPLC purity.
[00188] [00188] Step 11. (S) -Methyl 1-aminopropan-2-ylcarbamate hydrochloric acid salt. A solution of (S) -Benzyl 2 - (methoxycarbonylamino) propylcarbamate in methanol was hydrogenated over a 5% palladium / C catalyst in a 50 to 60 psi catalyst. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give a colorless oil. 60g of the colorless oil was dissolved in 200mL of dichloro-
[00189] [00189] Step 12. 3-Bromo-5-chloro-2-fliorbenzaldehyde. A solution of 2,2,6,6-tetramethylpiperidine (327 g, 98%, 2.274 moles) and THF (1.9 L, HPLC grade) was cooled to -75ºC (dry ice-methanol bath) under a argon atmosphere. 1.6 M n-BuLi / hexane solution (1.47 L, 2.35 moles) was added slowly to the mixture at -72 to -67 ° C for 1 h. The mixture was stirred at -72 to -67 ° C for 30 min to give a pale yellow suspension. 2-Bromo-4-chloro-1-fltorbenzene (435 g, 97%, 2.02 moles) was added slowly to the mixture at -72 to - 67 ° C for 30 min, and then the mixture was stirred at -72 to - 67 oC for another 30 min. Dimethylformamide (230 g, 99.5%, 3.14 mol) was added slowly to the mixture at -70 to -65 ° C for 30 min and then the mixture was stirred at -70 to -65 ° C for 30 min to obtain a light brown solution. The cooling bath was removed and then the saturated ammonium chloride solution (720 mL) was added to the batch at -60 to -30ºC for 15 min to obtain a cloudy mixture. 6 N hydrochloric acid was quickly added to the mixture at -30 to 10 ° C for 15 min at pH 1 and then ethyl acetate (2.0 L) was added at 10 to 20 ° C. The layers were separated and the aqueous layer was extracted with ethyl acetate (1 x 300 ml). The combined organic extracts were washed with water (1 x 800 ml) and brine (1 x 500 ml), dried over magnesium sulfate, and filtered. The filtrate was concentrated in vacuo (60-65 ° C) to give the title compound as a viscous brown oil, which solidified after standing after several hours. * H NMR (CDCl3): 5 7.76-
[00190] [00190] Step 13. 3-Bromo-5-chloro-2-fluorbenzoic acid. A stirred mixture of 3-bromo-S5-chloro-2-fluorbenzaldehyde (415 g), tert-butanol (1.2 L) and water (1.2 L) was heated to 30ºC and after potassium (335 g, 2.12 moles) was added (5 portions) to the batch at 40 to 45ºC for 1 h. The dark purple contents were heated in a model way from step 45 to 50 ° C for 30 min, 50 to 55 ° C for 30 min and 55 to 60 ° C for 30 min to obtain a purple-brown suspension. The reaction mixture was allowed to cool to 20ºC, of sodium, then saturated sulfite solution was added to 22 to 27ºC, until a negative peroxide test was obtained. Hot water (2.5 L, - 50ºC) and saturated sodium carbonate solution (100 mL) were added sequentially to the mixture for more than 15 min. The dark suspension was filtered through a 1 cm bed of celite, and the filter cake was washed with hot water (4 x 1 L, - 50 ° C). The combined filtrate was acidified with 6 N hydrochloric acid to pH 1 to obtain a yellow oily suspension. Ethyl acetate (3 L) was added to the mixture and the mixture was stirred for 10 min. The organic (top) layer was washed with water (1.2 L), dried over magnesium sulfate, filtered and concentrated in vacuo (60 to 65 ° C) to give a thick yellow suspension. Hexane (700 ml) was added to the residue and the suspension was cooled to 5 to 10ºC. The solid was collected by filtration, and the filter cake was dried under vacuum (65 ° C) overnight to give the title compound as a yellow solid. mp 150 to 152 ° C; HPLC purity (225 nm): 97.5%; 1 H NMR (d6-DMSO): 5 7.82 (s, 1H), 8.10 (s, 1H), 13.82 (br s, 1H), MS m / z 254 (M + H).
[00191] [00191] Step 14. Terc-butyl 3-bromo-S5-chloro-2-fluorophenylcarbamate. A mixture of 3-bromo-5-chloro-2-fluorbenzoic acid (243.9, 97.5%, 0.935 mol), triethylamine (105 g, 99.5%, 1.02 mol), and tert-butanol
[00192] [00192] Step 15.1 - (S) -methyl (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) -propan-2-ylcarbamate. 2-Chloro-4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) -pyrimidine was charged to a 4-neck flask equipped with a mechanical stirrer, a thermometer and a condenser under nitrogen purge. , 0 g), (S) -methyl 1-aminopropan-2-ylcarbamate hydrochloric acid salt (174.3 g), sodium carbonate (365.7 g) and DMSO (2400 ml). The mixture was heated with stirring for 18 h, at an internal temperature of 90ºC. The mixture was cooled to 40ºC. Toluene (3870 mL) was added at 37 to 43 ° C with stirring. Water (7200 mL) was added at 37 to 43 ° C. The toluene layer was separated at 37 to 43 ° C. For the toluene layer, 15% aqueous sodium chloride solution was added | (3.870 mL) and the pH of the aqueous solution. The layer was adjusted to pH - 5.0 by adding 10% aqueous citric acid solution at 37 to 43ºC. The required pH adjustment - 20 mL of 10% aqueous citric acid. The toluene layer was then washed with saturated aqueous sodium bicarbonate solution (2880 mL) at 37 to 43ºC. The toluene layer containing the title compound was used as an entry in step 17.
[00193] [00193] Step 16. 5-chloro-2-fluorine - 3- (4,4,5,5-tetramethyl-1l, 3,2-dioxabo-rolan-2-yl) tert-butyl phenylcarbamate. A flask equipped with a mechanical stirrer, thermometer, condenser, and heating blanket under nitrogen purge was charged with tert-butyl 3-bromo-5-chloro-2-fluorophenylcarbamate (33.0 g), bis (pinacolate) diboro (447.0 g), potassium acetate (405.6 g) and toluene (2700 ml). The mixture was stirred at room temperature for 15 min and PdClI2 (dppf) (50.4 g) was added. The mixture was then heated to 108 + 2 ° C. (Note: The mixture darkened at 50 to 60 ° C) A solution of tert-butyl 3-bromo-5-chloro-2-fluorophenylcarbamate (414 g) in toluene (1770 ml) was added at 108 + 2 ° C for 70 min . The mixture was kept at 108 + 2ºC for 15 h. The mixture was cooled to room temperature under a flow of nitrogen and then filtered through celite. The filtrate containing the title compound was used as an input in step 17
[00194] [00194] Step 17.1 - (S) -methyl (S) -methyl (4- (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) -propan-2-ylcarbamate charged 1 - (4 - (3-iodo-1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino) -propan-2-ylcarbate (S) -methyl (3870 ml of toluene solution , - 382 g, 0.861 mol) and 5-chloro-2-fluorine - 3- (4,4,5,5-tetramethyl-1,2,2-dioxaborolan-2-yl) tert-butyl phenylcarbamate (4470 ml of solution
[00195] [00195] Step18.1- (4- (3-amino-5-chloro-2-fluorophenyl) 1 - isopropyl -1H - pyrazol - 4 yl) pyrimidin -2-ylamino) -propan-2-ylcarbamate - methyl 1 - (4 - (3-amino-5-chloro-2-fluoro-phenyl) 1 - isopropyl -AH - pyrazol - 4 yl) pyrimidin -2-ylamino) -propan-2-ylcarbamate was loaded into a flask of (S) -methyl (- 7.3 L toluene solution, - 483.3 g, 0.86 mol) at 20ºC under a nitrogen atmosphere. To the solution, 12N HCl (574.3 mL, 6.95 moles) was added during - 20 min, keeping the temperature below 25ºC. The addition of HCl caused an exotherm from 19ºC to 24ºC. The mixture was stirred at 20 to 23 ° C for 1 h. To the reaction mixture, water (3100 mL) was added. The mixture was stirred min at 20 ° C. The aqueous layer was separated and washed with 2-methyl THF (3100 ml). A saturated aqueous potassium carbonate solution (- mL 778) was added slowly to the aqueous layer. The pH of the aqueous layer was - 8.5. The aqueous layer was extracted with 2-methylTHF (3825 ml). The 2-methyl THF layer was concentrated in vacuo (60 mmHg, 40 ° C). The residue was diluted with 2-methylTHF (- mL 3800) to provide a solution of the title compound, which was used directly as the step entry. 19. HPLC purity: 95%.
[00196] [00196] Step 19. 1- (4- (3- (5-chloro-2-fluorine-3- (N- (methylsulfonyl) methylsulfonamido) phenyl) -1-isopropyl-1H-pyrazole-4- il) pyrimidin-2-ylamino) propan-2-ylcarbamate of (S) - methyl. 1- (4- (3- (5-chloro-2-fluoro-3- (N- (methylsulfonyl)] methylsulfonamido) phenyl) -1-isopropyl-1H- was loaded into a flask
[00197] [00197] Step 20. N - [(28S) -1- (f4- [3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazole -4-yl] pyrimidin-2-yl «<amino) propan-2-yl | methyl carba-bush. 1- (4- (3- (5-chloro-2-fluoro-3- (N- (methylsulfonyl) methylsulfonamido) phenyl) -1-isopropyl-1H-pyrazol-4-yl) pyrimidin-2 was loaded into a flask -ylamino) (S) -methyl-propan-2-ylcarbamate (- 3.8 L methylTHF solution, - 531.5 g, 0.86 mol). To the solution, 3N aqueous sodium hydroxide (1782.8 mL, 5.34 moles) was added at 15 to 20ºC with stirring. The mixture was vigorously stirred at 20 to 23 ° C over 30 min and the stirring was stopped. The aqueous layer was discarded. 2N HCI (- 410 mL) was added to the organic layer to adjust the pH to 6.0 to 6.5, then saturated aqueous sodium bicarbonate solution (- 300 mL) was added to adjust the pH - 8, 5. The aqueous layer was discarded. The organic layer was washed with 15% aqueous sodium chloride solution (2000 mL). The organic layer was concentrated under vacuum (80 torr) at a bath temperature of 45 ° C to give a brown solution (780 g). The solution was diluted with 2-
[00198] [00198] The compounds in the following table 1 were prepared in a similar manner to the above examples, using the appropriate starting materials:
[00199] [00199] B-Raf (V600E; 4 pM) and biotinylated Mek (dead kinase; 10nM) were combined at 2X final concentrations in the assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl 2, 0, 01% BSA and 1 mM DTT) and dispensed 10 μl per well on assay plates (Greiner white 384 assay plates% 781207) containing 0.5 | u 40X of a compound of the present invention diluted in 100% DMSO. The plate was incubated for 60 minutes at room temperature.
[00200] [00200] The reaction of the B-Raf kinase activity was initiated by the addition of 10 | u per well of 2X PT (10 u M) diluted in assay buffer. After 3 hours, the reactions were stopped with the addition of 10 | u stop reagent (60 mM EDTA, 0.01% Tween 20). Phosphorylated product was measured using a rabbit anti-p-MEK antibody (cell signaling, t 9121) and the Alpha IgG (Protein) screen detection kit (PerkinElmer ft 6760617R), by adding 30 | hi to the well of an antibody mixture (1: 2000 dilution) and granule detection (1: 1000 dilution of both beads) in bead buffer (50 mM Tris, pH 7.5, 0.01 % Tween 20). The additions were made under dark conditions to protect the granules from light detection. A cap was placed on top of the plate and the plate was incubated for 1 hour at room temperature. The luminance was read on a PerkinElmer Envision instrument. The concentration of each compound for 50% inhibition (IC50) was calculated by non-linear regression using the XL Fit data analysis software.
[00201] [00201] The compounds of the present invention, in free form or in the form of pharmaceutically acceptable salt, exhibit valuable pharmacological properties, for example, as indicated by in vitro tests described in the present patent application. For example, the compounds of the present invention preferably have an IC50 in the range of 1 x 10-10 to 1 x 10-5 M, preferably less than 500 nm, 250 nm, 100 nM and 50 nM for B- Raf V600E.
[00202] [00202] For example, IC50 data for some compounds of the present invention in the Homogeneous Luminescence Proximity Assay are shown in the Table, supra. Example 123 A375 cell proliferation assay (A375 CP)
[00203] [00203] A375 is a melanoma cell line that hosts the B-Raf V600E mutation. A375-luc cells engineered to express luciferase are plated as clear bottom plates of 384 wells as 1,500 cells / 50 µl / well in DMEM containing 10% FBS. The compounds of the present invention dissolved in 100% DMSO in appropriate concentrations are transferred to the cells by means of a robotic Pin tool (100nl). The cells are incubated for 2 days at 25ºC, then 25 | u of BrightGloTM is added to each well and the plates are read by luminescence. The concentration of each compound for 50% inhibition (IC50) was calculated by non-linear regression using XL Fit data analysis software.
[00204] [00204] The compounds of the present invention, in free form or in the form of pharmaceutically acceptable salt, exhibit valuable pharmacological properties, for example, as indicated by in vitro tests described in the present patent application. For example, the compounds of the present invention preferably have an IC 50 in the range of less than 500 nm, 250 nm, 100 nM and 50 nM for the wild type and V600E B-Raf.
[00205] [00205] For example, the IC50 data of some compounds of the present invention in the A375 cell proliferation assay are shown in the Table, below.
[00206] [00206] The cells were seeded in RPMI 1640 + 10% FBS medium at a density of 30 x 103 cells per 96 wells in treated tissue culture plates, then incubated at 37ºC and 5% CO 2 for 24 hours before the compounds were added. The test compounds were serially diluted in DMSO, then added to the cells (final concentration of DMSO 0.1%) and incubated at 37ºC and 5% CO2 for 3 hours. pMEK and PERK levels were measured using a sandwich immunoassay kit (Meso Scale Discovery). The culture supernatants were removed and the cells were lysed by adding cold lysis buffer (provided in the kit) for 30 minutes with gentle agitation. For the detection of pMEK1 / 2 (Ser217 / 221) and pERK1 / 2 (Thr / Tyr202 / 204, Thr / Tyr185 / 187), lysates were added to the plates as a coated blocked antibody supplied with the kits and incubated during night at 4ºC with agitation. The plates were washed and the phosphoproteins detected using the labeled antibodies provided and read in a sector 6000 instrument. Example 125 Cell viability assay
[00207] [00207] SW620 cells were seeded in RPMI 1640 +% FBS medium at a density of 1500 cells per 96 wells in treated, lower, clear tissue culture plates. The test compounds were serially diluted in DMSO, then added to the cells (final concentration of DMSO 0.1%) and incubated at 37 ° C and 5% CO 2 for 4 days. To measure the viability of the cells, the cell plates were placed at room temperature, the culture media were removed, and 200 µL of reagent from the Titer-Glo cell (Promega, the kit components mixed, according to the manufacturer's protocol, in then diluted 1: 2 with growth medium) was added to each well. The plates were shaken for 5 minutes, then incubated at room temperature for 5 minutes, and luminescence was measured (Trilux, Perkin Elmer). Example 126 Rat1 soft agarose assay
[00208] [00208] Rat1i cells were suspended in 1% dagarose (Lonza) at a density of 1000 cells per 96 wells. The agar / cell mixture was allowed to solidify. The test compounds were serially diluted in DMSO, then added to the upper part of the agarose cell mixture (final concentration of 0.2% DMSO) and incubated at 37ºC and 5% CO2. After 17 days, colon growth was determined by incubating cells with AlBlue (Diagnostics TREK) and measuring metabolic activity with a Spectramax reader plate (Molecular Devices, Inc; absorbance measured at 562 nm). Example 127 Microsomal Liver Clearance Assay
[00209] [00209] The in vitro microsomal clearance test was designed to assess the potential risks associated with the hepatic metabolic stability of compounds. The test compound (1 µM) was incubated with liver microsomes (0.5 mg / mL) from different species (mouse, rat, monkey, dog and human) and NADPH (1 mM) in phosphate buffer 100 mM potassium at 370C. At specific reaction time points (0, 5, 10 and 30 minutes), reaction aliquots were removed and the reactions were terminated by the addition of cold acetonitrile containing internal standard mass spectrometry. The samples were centrifuged and the supernatants were analyzed by LC-MS / MS. In vitro (t1 / 2, min) and intrinsic (Clint, uL / min / mg) metabolic clearance are based on the rate and extent of test compound metabolism, as determined by the disappearance of the compound original from the reaction mixture. These values can be scaled to prevent the hepatic metabolic clearance rate (CLH, ml / min / kg) and the extraction ratio (ER, expressed as a proportion of the metabolic liver clearance to the hepatic blood flow in the species). In general, compounds with high predicted CLint or ER in vitro are considered to be at high risk for exposure-limiting metabolism in vivo.
[00210] [00210] The measured extraction ranges for some compounds of the present invention are given in the table below. [compound [Esrutara TerHmeno | ERCamundonso | THE
[00211] [00211] A549 cells were stably transfected with the promoter reporter IL-8 directed by pGL3-IL8-Luc. The cells were plated as a 4x105 / ml in 384 solid wells of white plates (40ul / well, 5% CD-FBS, 1xP / S, DMEM) and were incubated overnight (18 to 20 hours) at 37 ° C. oC. The test compounds were serially diluted in DMSO, then 50 ml of the test solution was added to the incubation (final DMSO concentration 0.1%). After incubation with the test compound for 30 min, the cells were stimulated with 1ng / ml beta IL-1 (10ul of 5ng / ml solution per well). Bright-Glo (25ul / well) was added in order to measure luciferase expression after 7 to 8 hours of stimulation. The IC 50 data for some compounds of the present invention are given in the table below.
[00212] [00212] Total pharmacokinetic study: male Balb / c mice (n = 3, body weights 22-25 g) or male Wistar rats (n = 3, body weights 250-300 g) were administered intravenously test post through the side of the tail of the vein or orally through an esophageal tube. The formulation was typically a dose of 2.5 mg / ml solution of the compound in 75% PEG300 and 25% D5W. Six blood samples of 50 µl each were collected in series for 24 h after administration. Blood samples were centrifuged to separate the plasma. Plasma samples were analyzed and quantified using LC-MS / MS.
[00213] [00213] Rapid pharmacokinetic study: male Balb / c mice (n = 3, body weights 22-25 g) or male Wistar rats (n = 3, body weights 250-300 g) were administered the test compound via intravenous (IV) through the lateral vein of the tail or orally (PO), through an esophageal tube. The formulation was typically a dose of 2.5 mg / ml of solution of the compound in 75% PEG300 and 25% D5W. Six blood samples of 50 µl each were collected in series for 24 h after administration. The blood samples were centrifuged and the plasma separated and collected over the three animals at each time point via the dose. Plasma samples were analyzed and quantified using LC-MS / MS.
[00214] [00214] For both complete and rapid pharmacokinetic studies, the following parameters were calculated by non-compartmental regression analysis using WinNonlin 5.0 software (Pharsight, Mountain View, CA, USA): plasma clearance (CI), the maximum plasma concentration (Cmax), plasma area under the concentration-time curve- (ASCO-inf), and percent oral bioavailability (F%).
[00215] [00215] The pharmacokinetic parameters in mice for some compounds of the present invention are given in the table below.
[00216] [00216] The compounds of Formula |, in free form or in the form of pharmaceutically acceptable salt, exhibit valuable pharmacological properties, for example, as indicated by the in vitro and in vivo tests described in the present patent application. For example, compounds of Formula | they preferably present an IC50 in the 375 CP cell proliferation assay in the 250nm or better range, preferably less than 200nM, 150nm, 100 nM and 50 nM.
[00217] [00217] The 2- (methoxycarbonylamino) -1-propyl group in R1 predicts a preferred level of activity and selectivity over other kinases, including p38. For example, a greater than 30-fold increase in activity exists between compounds 9 and 29, where A375 CI50 is 2nM and T6nNM, respectively.
[00218] [00218] The phenyl substitution pattern of compounds of Formula lb is great for metabolic stability (ER in mice and humans) with fluorine or chlorine in the R5 position and fluorine, chlorine, or methyl in the R3 position. Compare, for example, ER (human) in compounds 9 and 6 of <0.21 and 0.69, respectively.
[00219] [00219] The combination of the group 2 - (methoxycarbonylamino) -1-propyl in R1, the substitution pattern R1 and R3 / R5 and the methyl group R4 has a surprising effect on total drug exposure (AUC). See, for example, compound 9 (compared to compounds 1, 3, 4.6 and 7), AUC wave, at an oral dose of 10 mg / kg, is 30 + 4 hours * micromolar. Example 130 In vivo efficacy - 14 days in Model A375 mouse xenograft
[00220] [00220] A375 cells were cultured under sterile conditions in a 37ºC incubator with 5% CO2 for two to four weeks. The cells were cultured in RPMI-1640 medium supplemented with 10% FBS. The cells were run twice a week with 0.05% trypsin / EDTA. On the day of implantation, the cells were
[00221] [00221] “Compound 9 (formulated in 20% ETPGS PEG300 / 3% / 77% water) was dosed according to the above protocol, using the following dosing regimen: Group 1: Vehicle, qd x14 Group 2: 1 mg / kg Cpd 9, bid x14 Group 3: 3 mg / kg Cpd 9, bid x14 Group 4: 10 mg / kg Cpd 9, bid x14 Group 5: 20 mg / kg Cpd 9, bid x14
[00222] [00222] Tumor volume results were assessed 14 days after the first dose. The partial response is defined as having a tumor growth of 20 to 50% of the growth of the control tumor. Stable disease is defined as having the final tumor volume within +/- 20% of the initial tumor size. Partial regression is defined as having the final tumor volume <80% of the initial tumor volume.
[00223] [00223] It is understood that the examples and modalities described in the present invention are for illustrative purposes only and that various modifications or alterations in light of them will be suggested for those who are skilled in the art and are to be included within the spirit and scope of the present patent application and scope of the appended claims. All publications, patents, and patent applications cited in the present invention are hereby incorporated by reference for all purposes.

权利要求:
Claims (25)
[1]
1. Compound, characterized by the fact that it presents Formula la: R3 Y, / AN Ro NX O, = Ss Ra
NH NOS RA INÂANÊ no o NÚ ON NY N [E
N
À R7 la in which Y is selected from N and CR; R2, R3, R5 and Rg are independently selected from hydrogen, halo, cyano, C1-4 alkyl, C1-1-4 alkyl substituted by halo, C1-4 alkoxy and C1-4 alkoxy substituted by halo; with the proviso that when Rs is fluorine, Ra and Rg are not both hydrogen; Ra is selected from -R9 and -NR10R11; where Ro is selected from Ci.salquila, Ca.gcycloalkyl, Ca-sheterocycloalkyl, aryl and heteroaryl; where alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl of Ro is optionally substituted with 1 to 3 radicals independently selected from halo, cyano, C14alkyl, Ci4alkyl substituted by halo, Ci4alkoxy and Cisalcoxy substituted by halo; and Rio and R11 are independently selected from hydrogen and Ro; R7 is selected from Ci4alkyl, Ca-scicloalkyl and Ca.5 heterocycloalkyl, where alkyl, cycloalkyl or heterocycloalkyl of R7 is optionally substituted with 1 to 3 radicals independently selected from halo, cyano, hydroxyl, Ci4alkyl, Ci -4 halo substituted alkyl, C1-4 alkoxy and halo substituted C1-14 alkoxy; or R; is hydrogen, and N-oxide derivatives, tautomers, pharmaceutically
pharmaceutically acceptable solvates (for example hydrates) of such compounds.
[2]
2. Compound, according to claim 1, characterized by the fact that R; it is selected from Ci4alkyl, Ca-sciclo-alkyl and C3a.sheterocycloalkyl, in which R, alkyl, cycloalkyl or hetero-cycloalkyl; it is optionally substituted with 1 to 3 radicals independently selected from halo, cyano, hydroxyl, C1-4alkyl, C1-4alkyl substituted by halo, C1-4alkoxy and C1-4alkoxy substituted by halo.
[3]
3. A compound according to claim 1 or 2, characterized by the fact that Ra is -Ro; where Ro is selected from C1-3alkyl and Ca.gcycloalkyl; wherein alkyl or cycloalkyl of Rg is optionally substituted with 1 to 3 radicals independently selected from halo and -C1-, alkyl substituted by halo.
[4]
4. Compound, according to claim 3, characterized by the fact that: R2 is selected from hydrogen and fluorine; R3 is selected from chlorine, fluorine and methyl; Rs is selected from hydrogen, chlorine and fluorine; Y is selected from N and CR; and Rs is selected from hydrogen and fluorine.
[5]
5. Compound according to claim 1, characterized by the fact that it is selected from: N - [(28) -1 - ((4- [3- (3-ethanesulfonamido-2 4-difluorphenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl «<amino) propan-2-yl | methyl carbamate; N - [(28) -2 - ((4 - methyl [3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) - 1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl) amino) propyl | carbamate ; N - [(28) -1 - ((4- [3- (5-chloro-2-fluoro-3-methanesulfonamidophenyl) -
1- (oxan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl) amino) propan-2-yl | methyl carbamate; and N - [(28) -1 - ((4- [3- (5-chloro-2-fluoro-3-methanesulfonamidophenyl) - 1H-pyrazol-4-yl] pyrimidin-2-yl) amino) propan-2 -il] | methyl carbamate.
[6]
6. Compound according to claim 1, characterized by the fact that it presents the Formula lb: d R3 L AR ss inA node So N = H / À Rs to lb in which R3 is selected from chlorine, fluorine and methyl; R5 is selected from fluorine and chlorine; and R7 is selected from ethyl and isopropyl.
[7]
7. Compound, according to claim 1, characterized by the fact that it is selected from: N - [(28) -1 - ((4- [3- (5-chloro-2-fluorine-3 -methanesulfonamidophenyl) - 1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl ') amino) propan-2-yl | methyl carbamate; N - [(28) -1 - [(4- (3- [3-chloro-5- (propane-1-sulfonamido) phenyl] -1- (propan-2-yl) -1H-pyrazol-4-yl ) pyrimidin-2-yl) amino] propan-2-yl | methyl carbamate; N - [(28) -1 - ((4- [3- (3-chloro-2-methanesulfonamidopyridin-4-yl) - 1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin- 2-yl ') amino) propan-2-yl | methyl carbamate; N - [(28) -1- (14- [3- (3-fluoro-2-methanesulfonamidopyridin-4-yl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2 -yl «<amino) propan-2-yl | methyl carbamate;
N - [(28) -1 - ((4- [3- (2-chloro-3-ethanesulfonamido-4,5-difluorphenyl) -1- (propan-2-yl) -1H-pyrazol-4- il] Jpirimidin-2-ilyamino) propan-2-yl] methyl carbamate;
N - [(28) -1- (14- [3- (2,4-difluoro-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl «<amino) propan-2-yl | methyl carbamate;
N - [(28) -1- (f4- [1- (propan-2-yl) -3- (2,4,5-trifluor-3-methanesulfon-fonamidophenyl) -1H-pyrazol-4-yl] pyrimidin -2-yl (<> amino) propan-2-yl | methyl carbamate;
N - [(28) -1 - ((4- [3- (3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] Jpirimidin-2-yl; yamino) propan- Methyl 2-yl | carbamate;
N - [(28) -1 - [(4- (3- [2,4-difluoro-3- (propane-1-sulfonamido) phenyl] - 1- (propan-2-yl) -1H-pyrazol-4 -yl) pyrimidin-2-yl) amino] propan-2-yl | methyl carbamate;
N - [(28) -1- (f4- [3- (3-cyclopropanesulfonamido-2,5-difluorphenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] Jpirimidin-2 -ilyamino) propan-2-yl] methyl carbamate;
N - [(28) -1 - ((4- [3- (5-chloro-3-cyclopropanesulfonamido-2-fluorophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin- Methyl 2-yl; (amino) propan-2-yl] carbamate;
N - [(28) -1 - [(4- (3- [5-chloro-2-fluor-3- (propane-1-sulfonamido) phenyl] -1- (propan-2-yl) -1H-pyrazole -4-yl) pyrimidin-2-yl) amino] propan-2-yl] methyl carbamate;
N - [(28) -1 - [(4- (3- [2,6-difluoro-3- (propane-1-sulfonamido) phenyl] - 1- (propan-2-yl) -1H-pyrazol-4 methyl -yl) pyrimidin-2-yl) amino] propan-2-illcarbamate;
N - [(28) -1-1 [4- (3- (2-fluorine-3 - [(3,3,3 trifluorpropane) sulfone-midolfenyl) -1- (propan-2-yl) -1H-pyrazole -4-yl) methyl pyrimidin-2-yl) propan-2-illcarbamate;
N - [(28) -1 - [(4- (3- [2-fluoro-3- (propane-1-sulfonamido) phenyl] -1- (propan-2-yl) -1H-pyrazol-4-yl ) pyrimidin-2-yl) amino] propan-2-yl | methyl carbamate; N - [(28) -1- (14- [3- (2-fluoro-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl «< amino) methyl propan-2-yl | carbamate; N - [(28) -1- (14- [3- (2,5-difluoro-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl «<amino) propan-2-yl | methyl carbamate; N - [(28) -1 - ((4- [3- (5-chloro-2-fluoro-3-methanesulfonamidophenyl) - 1-ethyl-1H-pyrazol-4-yl] pyrimidin-2-yl) amino) propan-2-yl | methyl carbamate; N - [(28) -1- (14- [3- (2-fluor-3-methanesulfonamido-5-methylphenyl) - 1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2 -yl ') amino) propan-2-yl | methyl carbamate; N - [(28) -1 - ((4- [3- (2-chloro-3-methanesulfonamido-S5-methylphenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] Jpirimidin-2-ilyamino) propan-2-yl] methyl carbamate; N - [(28) -1 - ((4- [3- (2-chloro-5-fluoro-3-methanesulfonamidophenyl) - 1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl «) amino) propan-2-yl | methyl carbamate; N - [(2R) -1- (f4- [ 3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pyrimidin-2-yl «<> amino) propan-2-yl | methyl carbamate, and N - [(28) -1- (14- [3- (2,5-dichloro-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4- yl] pyrimidin-2-yl «<amino) propan-2-yl | methyl carbamate.
[8]
8. Compound, according to claim 1, characterized by the fact that it is:
NY
HNS E. Ne cl = Da As NA o | Give H 2N |
[9]
9. Pharmaceutical composition, characterized by the fact that it comprises a compound, as defined in any one of claims 1 to 8, mixed with at least one pharmaceutically acceptable excipient.
[10]
10. Pharmaceutical composition according to claim 9, characterized by the fact that the excipient is selected from the group comprising corn starch, potato starch, tapioca starch, starch paste, pregelatinized starch , sugars, gelatin, natural gums, synthetic gums, sodium alginate, alginic acid, tragacanth, guar gum, cellulose, ethyl cellulose, cellulose acetate, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, magnesium aluminum silicate, polyvinylpyrrolidone, talc, calcium carbonate, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, agar, sodium carbonate, sodium croscarmellose, crospovidone, potassium polacracine , sodium starch glycolate, clays, sodium stearate, calcium stearate, magnesium stearate, stearic acid, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, others glycols, sodium lauryl sulfate, hydrogenated vegetable oil, peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, soybean oil, zinc stearate, sodium oleate, oleate of ethyl, ethyl laureate, silica, and combinations thereof.
[11]
11. Pharmaceutical composition according to claim 9, characterized by the fact that it also comprises an additional therapeutic agent.
[12]
12. Pharmaceutical composition according to claim 11, characterized by the fact that the additional therapeutic agent is selected from an anti-cancer compound, an analgesic, an antiemetic, an antidepressant and an anti-inflammatory agent.
[13]
13. Use of the compound, as defined in any of claims 1 to 8, characterized by the fact that it is for the manufacture of a cancer treatment drug.
[14]
14. Use, according to claim 13, characterized by the fact that the cancer to be treated is selected from the group comprising lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, cancer of the prostate, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract and nervous system.
[15]
15. Use according to claim 13 or 14, characterized by the fact that it still comprises an additional therapeutic agent, in which the additional therapeutic agent is administered to the individual simultaneously with the compound.
[16]
16. Use according to claim 13 or 14, characterized by the fact that it further comprises administering the additional therapeutic agent to the individual, wherein the additional therapeutic agent is administered to the individual sequentially as the compound.
[17]
17. Use according to claim 16, characterized by the fact that the compound of Formula | is N - [(28S) -1 - ((4- [3- (5-chloro-2-fluor-3-methanesulfonamidophenyl) -1- (propan-2-yl) -1H-pyrazol-4-yl] pirimi - din-2-yl) amino) propan-2-yl | methyl carbamate.
[18]
18. Use according to any one of claims 14 to 17, characterized in that the additional therapeutic agent comprises an anti-cancer drug, a pain medication, an antiemetic agent, an antidepressant or anti-inflammatory.
[19]
19. Use according to any one of claims 17, characterized by the fact that the additional therapeutic agent is a different Raf kinase inhibitor or an MEK, mTOR, HSP90, AKT, PI3SK, CDK9, PAK, protein kinase inhibitor C, a MAP kinase, a MAPK kinase, or ERK.
[20]
20. Use, according to claim 19, characterized by the fact that the MEK inhibitor is selected from AS703026; MSC1936369B; GSK1120212; AZD6244; PD-0325901; ARRY-438162; RDEA119; GDCO0941; GDCO0973; TAK-733; RO5126766 and XL-518.
[21]
21. Use according to any one of claims 14 to 20, characterized by the fact that the cancer is melanoma or colorectal cancer.
[22]
22. Use according to claim 21, characterized by the fact that melanoma is metastatic or colorectal cancer is colon carcinoma.
[23]
23. Use according to any one of claims 13 to 22, characterized in that the compound is for treating a condition mediated by means of Raf kinase.
[24]
24. Use according to claim 23, characterized by the fact that Raf kinase is a mutant b-Raf kinase
[25]
25. Use according to claim 24, characterized by the fact that the mutant b-Raf kinase is b-Raf (V600E).

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10568884B2|2020-02-25|Compounds and compositions as protein kinase inhibitors

---

BR112013026137B1|2020-12-01|substituted pyrimidinyl-pyrroles as kinase inhibitors

---

US10875863B2|2020-12-29|RIPK2 inhibitors and method of treating cancer with same

---

ES2807539T3|2021-02-23|Imidazole-piperidinyl derivatives as modulators of kinase activity

---

TWI480276B|2015-04-11|Compounds and compositions as protein kinase inhibitors

---

KR20220028075A|2022-03-08|Tyrosine kinase non-receptor 1 | inhibitors and uses thereof

---

WO2019012172A1|2019-01-17|New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 |

---

BR112012011287A2|2020-09-01|kinase inhibitor compounds, their pharmaceutical formulation and their uses

同族专利:

---

公开号 | 公开日

---

CA2771775A1|2011-03-03|

---

CN102725283A|2012-10-10|

---

CN103896921A|2014-07-02|

---

AU2010286569A1|2012-04-12|

---

CA2771775C|2015-01-20|

---

HUS1900013I1|2019-04-29|

---

US9850229B2|2017-12-26|

---

EA025222B1|2016-12-30|

---

DK2470526T3|2014-08-25|

---

US20160122324A1|2016-05-05|

---

US20160280686A1|2016-09-29|

---

DK2727918T3|2017-01-23|

---

LTC2470526I2|2020-04-27|

---

US20160120866A1|2016-05-05|

---

UA112285C2|2016-08-25|

---

US9850230B2|2017-12-26|

---

US10568884B2|2020-02-25|

---

NO2019012I1|2019-03-05|

---

RS55568B1|2017-05-31|

---

AR077975A1|2011-10-05|

---

AU2010286569C1|2019-11-28|

---

CU24110B1|2015-07-30|

---

HUE032847T2|2017-11-28|

---

DOP2012000051A|2012-05-31|

---

AU2010286569B2|2013-10-10|

---

SG178351A1|2012-03-29|

---

CY1118452T1|2017-07-12|

---

CN103896921B|2016-02-24|

---

LT2727918T|2017-01-25|

---

UY32860A|2011-03-31|

---

MY156259A|2016-01-29|

---

NI201200029A|2012-05-29|

---

US20180297986A1|2018-10-18|

---

EA201500175A1|2015-05-29|

---

JP6045519B2|2016-12-14|

---

CU20120034A7|2012-06-21|

---

US10005761B2|2018-06-26|

---

PE20120861A1|2012-07-14|

---

IL218084A|2016-11-30|

---

US20180297985A1|2018-10-18|

---

LTPA2019005I1|2019-03-25|

---

LTPA2019006I1|2019-03-25|

---

PL2727918T3|2017-06-30|

---

ME01860B|2014-12-20|

---

SI2470526T1|2014-09-30|

---

KR101413392B1|2014-06-27|

---

SG10201405311TA|2014-09-26|

---

EA201200373A1|2012-09-28|

---

WO2011025927A1|2011-03-03|

---

EP2470526B1|2014-05-28|

---

US9314464B2|2016-04-19|

---

LUC00101I1|2019-02-13|

---

GT201200053A|2014-03-27|

---

ES2610825T3|2017-05-03|

---

CL2012000340A1|2012-08-17|

---

US10576080B2|2020-03-03|

---

PT2727918T|2017-01-20|

---

PL2470526T3|2014-10-31|

---

SMT201400133B|2014-11-10|

---

EP2727918B1|2016-10-12|

---

KR20120062839A|2012-06-14|

---

BR112012004453A8|2021-06-08|

---

HRP20140799T1|2014-11-07|

---

MX2012002546A|2012-04-11|

---

US20110306625A1|2011-12-15|

---

ECSP12011700A|2012-03-30|

---

HN2012000441A|2015-01-05|

---

MA33604B1|2012-09-01|

---

CR20120102A|2012-05-02|

---

EP2470526A1|2012-07-04|

---

US20200323852A1|2020-10-15|

---

US9593099B2|2017-03-14|

---

HUS1900012I1|2019-04-29|

---

US20160263113A1|2016-09-15|

---

IN2012DN02469A|2015-08-21|

---

CN102725283B|2014-02-26|

---

HK1167390A1|2012-11-30|

---

SMT201700036B|2017-03-08|

---

JP5475888B2|2014-04-16|

---

SI2727918T1|2017-02-28|

---

US9593100B2|2017-03-14|

---

ES2492499T3|2014-09-09|

---

EP2727918A1|2014-05-07|

---

CO6612222A2|2013-02-01|

---

ME02684B|2017-06-20|

---

NZ598924A|2013-07-26|

---

LUC00101I2|2020-01-23|

---

RS53489B1|2015-02-27|

---

JP2014098022A|2014-05-29|

---

ZA201202020B|2012-12-27|

---

JP2013503186A|2013-01-31|

---

PT2470526E|2014-09-01|

---

IL218084D0|2012-04-30|

---

HRP20170005T1|2017-03-10|

---

US20130296318A1|2013-11-07|

---

TN2012000081A1|2013-09-19|

---

US20160280687A1|2016-09-29|

---

US8501758B2|2013-08-06|

---

JO3002B1|2016-09-05|

---

NO2019011I1|2019-03-05|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US4104250A|1976-08-11|1978-08-01|Borg-Warner Corporation|Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents|

---

JPS5475888A|1977-11-29|1979-06-18|Jiyasuko Kk|Surgical laser|

---

DE3571974D1|1984-12-06|1989-09-07|Pfizer|Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them|

---

US6358932B1|1994-05-31|2002-03-19|Isis Pharmaceticals, Inc.|Antisense oligonucleotide inhibition of raf gene expression|

---

US6391636B1|1994-05-31|2002-05-21|Isis Pharmaceuticals, Inc.|Antisense oligonucleotide modulation of raf gene expression|

---

US6037136A|1994-10-24|2000-03-14|Cold Spring Harbor Laboratory|Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto|

---

EP0952770A4|1995-09-07|1999-12-22|Fuisz Technologies Ltd|System for rendering substantially non-dissoluble bio-affecting agents bio-available|

---

US5717100A|1995-10-06|1998-02-10|Merck & Co., Inc.|Substituted imidazoles having anti-cancer and cytokine inhibitory activity|

---

AU728701B2|1996-05-23|2001-01-18|Applied Research Systems Ars Holding N.V.|Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same|

---

AR012634A1|1997-05-02|2000-11-08|Sugen Inc|QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE|

---

US6514977B1|1997-05-22|2003-02-04|G.D. Searle & Company|Substituted pyrazoles as p38 kinase inhibitors|

---

CN1264377A|1997-05-22|2000-08-23|G·D·西尔公司|Substituted pyrazoles as P38 kinase inhabitors|

---

US6187799B1|1997-05-23|2001-02-13|Onyx Pharmaceuticals|Inhibition of raf kinase activity using aryl ureas|

---

GB9716557D0|1997-08-06|1997-10-08|Glaxo Group Ltd|Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity|

---

US6022884A|1997-11-07|2000-02-08|Amgen Inc.|Substituted pyridine compounds and methods of use|

---

US6204467B1|1998-03-24|2001-03-20|Ford Global Technologies, Inc.|Method and apparatus for resistive welding|

---

ME00275B|1999-01-13|2011-02-10|Bayer Corp|?-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors|

---

US6316435B2|1999-02-24|2001-11-13|Supergen, Inc.|Combination therapy for lymphoproliferative diseases|

---

ES2398643T3|1999-12-23|2013-03-20|Mayne Pharma International Pty Ltd.|Enhanced pharmaceutical compositions for sparingly soluble drugs|

---

AU8534901A|2000-08-30|2002-03-13|Univ Arkansas|Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2|

---

PE20020354A1|2000-09-01|2002-06-12|Novartis Ag|HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE INHIBITORS|

---

DE60224299T2|2001-10-25|2008-12-11|Novartis Ag|COMBINATION MEDICATIONS WITH A SELECTIVE CYCLOOXYGENASE 2 INHIBITOR|

---

JP4399265B2|2001-12-21|2010-01-13|ヴァーナリス（ケンブリッジ）リミテッド|3,4-Diarylpyrazoles and their use in the treatment of cancer|

---

MXPA06003163A|2003-09-23|2006-06-05|Novartis Ag|Combination of a vegf receptor inhibitor with a chemotherapeutic agent.|

---

EP1692113B1|2003-11-14|2017-09-27|Lorus Therapeutics Inc.|Aryl imidazoles and their use as anti-cancer agents|

---

MXPA06007820A|2004-01-09|2006-09-01|Novartis Ag|Phenyl-[4--pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors.|

---

CN1960988B|2004-06-10|2012-01-25|Irm责任有限公司|Compounds and compositions as protein kinase inhibitors|

---

US20060058311A1|2004-08-14|2006-03-16|Boehringer Ingelheim International Gmbh|Combinations for the treatment of diseases involving cell proliferation|

---

CN101175755A|2005-03-17|2008-05-07|诺瓦提斯公司|N- [3- -phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase|

---

US20070099856A1|2005-05-13|2007-05-03|Gumerlock Paul H|Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen|

---

WO2007021966A1|2005-08-12|2007-02-22|Synta Pharmaceuticals Corp.|Pyrazole compounds that modulate hsp90 activity|

---

JP2009504796A|2005-08-22|2009-02-05|ノバルティスアクチエンゲゼルシャフト|PHARMACEUTICAL COMPOSITION COMPRISING A PH-DEPENDENT PHARMACEUTICAL COMPOUND, A PH ADJUSTING AGENT AND A RETARDANT|

---

WO2007024843A2|2005-08-26|2007-03-01|Smithkline Beecham Corporation|Pyrimidinyl-pyrazole inhibitors of aurora kinases|

---

PE20070427A1|2005-08-30|2007-04-21|Novartis Ag|BENZIMIDAZOLES DERIVED COMPOUNDS SUBSTITUTED AS TYROSINE KINASE INHIBITORS|

---

WO2007105058A2|2006-03-16|2007-09-20|Pfizer Products Inc.|Pyrazole compounds|

---

BRPI0710291A2|2006-04-05|2011-08-09|Novartis Ag|therapeutic agent combinations for cancer treatment|

---

US7501430B2|2006-04-17|2009-03-10|Arqule, Inc.|RAF inhibitors and their uses|

---

CA2662937A1|2006-09-11|2008-03-20|Curis, Inc.|Multi-functional small molecules as anti-proliferative agents|

---

BRPI0717586A2|2006-09-18|2013-10-29|Boehringer Ingelheim Int|METHOD FOR TREATING CANCER PRESENTING EGFR CHANGES|

---

BRPI0719797A2|2006-10-02|2017-10-24|Irm Llc|compounds and compositions as protein kinase inhibitors|

---

KR20090063240A|2006-10-06|2009-06-17|아이알엠 엘엘씨|Protein kinase inhibitors and methods for using thereof|

---

EP2120900A2|2007-02-15|2009-11-25|Novartis AG|Combination of lbh589 with other therapeutic agents for treating cancer|

---

US20090022789A1|2007-07-18|2009-01-22|Supernus Pharmaceuticals, Inc.|Enhanced formulations of lamotrigine|

---

CN101815712A|2007-08-01|2010-08-25|辉瑞有限公司|Pyrazole compound and as the purposes of RAF inhibitor|

---

UA100865C2|2007-10-19|2013-02-11|Эбботт Гмбх Унд Ко. Кг|Normal;heading 1;heading 2;heading 3;SOLID DISPERSION PRODUCT OF N-ARYL UREA-BASED DRUGS|

---

US8785486B2|2007-11-14|2014-07-22|Janssen Pharmaceuticals, Inc.|Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors|

---

WO2009115572A2|2008-03-21|2009-09-24|Novartis Ag|Novel heterocyclic compounds and uses therof|

---

SG190624A1|2008-05-06|2013-06-28|Glaxosmithkline Llc|Benzene sulfonamide thiazole and oxazole compounds|

---

US8541575B2|2008-07-24|2013-09-24|Nerviano Medical Sciences S.R.L.|3,4-diarylpyrazoles as protein kinase inhibitors|

---

NZ590747A|2008-07-28|2012-11-30|Gilead Sciences Inc|Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds|

---

US8778929B2|2008-09-29|2014-07-15|Boehringer Ingelheim International Gmbh|Substituted heteroaryl inhibitors of B-RAF|

---

WO2010041051A1|2008-10-07|2010-04-15|Astrazeneca Uk Limited|Pharmaceutical formulation 514|

---

US20110293750A1|2008-11-11|2011-12-01|Yale University|Activated wnt-beta-catenin signaling in melanoma|

---

ES2422263T3|2008-12-19|2013-09-10|Nerviano Medical Sciences Srl|Bicyclic pyrazoles as protein kinase inhibitors|

---

AR075180A1|2009-01-29|2011-03-16|Novartis Ag|SOLID ORAL FORMULATIONS OF A PYRIDOID-PYRIMIDINONE|

---

RU2402602C1|2009-02-12|2010-10-27|Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН|CELL LINE OF HUMAN MELANOMA mel Rac, APPLIED FOR OBTAINING ANTITUMOUR VACCINE|

---

WO2010100127A1|2009-03-04|2010-09-10|Novartis Ag|Disubstituted imidazole derivatives as modulators of raf kinase|

---

TWI532484B|2009-06-08|2016-05-11|艾伯維有限公司|Solid dispersions containing an apoptosis-promoting agent|

---

ES2679379T3|2009-06-15|2018-08-24|Nerviano Medical Sciences S.R.L.|Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and use as kinase inhibitors|

---

KR101256018B1|2009-08-20|2013-04-18|한국과학기술연구원|1,3,6-Substituted indole derivatives having inhibitory activity for protein kinase|

---

US8242260B2|2009-08-28|2012-08-14|Novartis Ag|Compounds and compositions as protein kinase inhibitors|

---

JO3002B1|2009-08-28|2016-09-05|Irm Llc|Compounds and compositions as protein kinase inhibitors|

---

BR112012017705B1|2010-01-27|2020-03-24|Nerviano Medical Science S.R.L.|3,4-DIARYLPIRAZOL SULPHONAMID DERIVATIVES AS PROTEIN KINASE INHIBITORS|

---

NZ603156A|2010-03-30|2014-10-31|Verseon Corp|Multisubstituted aromatic compounds as inhibitors of thrombin|

---

US9114137B2|2010-08-03|2015-08-25|Nerviano Medical Sciences S.R.L.|Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents|

---

US20140093565A1|2011-03-21|2014-04-03|Valcuria Ab|A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof|

---

EP2720696B1|2011-06-14|2016-05-25|Novartis AG|Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm|

---

AU2012335663B2|2011-11-11|2015-12-24|Array Biopharma Inc.|Method of treating a proliferative disease|

---

DK2782557T3|2011-11-23|2018-12-10|Array Biopharma Inc|PHARMACEUTICAL FORMULATIONS|

---

BR112015010477A2|2012-11-08|2017-07-11|Novartis Ag|A pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases.|JO3002B1|2009-08-28|2016-09-05|Irm Llc|Compounds and compositions as protein kinase inhibitors|

---

KR101814223B1|2010-02-25|2018-01-02|다나-파버 캔서 인스티튜트 인크.|Braf mutations conferring resistance to braf inhibitors|

---

US8907270B2|2010-06-30|2014-12-09|Schlumberger Technology Corporation|Method and apparatus for gain regulation in a gamma detector|

---

AU2012335663B2|2011-11-11|2015-12-24|Array Biopharma Inc.|Method of treating a proliferative disease|

---

DK2782557T3|2011-11-23|2018-12-10|Array Biopharma Inc|PHARMACEUTICAL FORMULATIONS|

---

US9408885B2|2011-12-01|2016-08-09|Vib Vzw|Combinations of therapeutic agents for treating melanoma|

---

CN103159736B|2011-12-10|2015-05-13|通化济达医药有限公司|Substitutional pyrazol kinase inhibitor|

---

UY34540A|2011-12-23|2013-06-28|Millennium Pharm Inc|HETEROARILOS AND USES OF THE SAME|

---

CA2864169A1|2012-03-28|2013-10-03|Caroline Emery|C-raf mutants that confer resistance to raf inhibitors|

---

US8716226B2|2012-07-18|2014-05-06|Saint Louis University|3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists|

---

EP2875021B1|2012-07-18|2017-08-23|Saint Louis University|Beta amino acid derivatives as integrin antagonists|

---

AR091876A1|2012-07-26|2015-03-04|Novartis Ag|PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES|

---

ES2717911T3|2012-08-07|2019-06-26|Novartis Ag|Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor|

---

CA2879252C|2012-08-17|2017-10-10|F. Hoffmann-La Roche Ag|Combination therapies for melanoma comprising administering cobimetinib and vemurafinib|

---

US20150232452A1|2012-09-19|2015-08-20|Ruga Corporation|Novel raf kinase inhibitors|

---

BR112015010477A2|2012-11-08|2017-07-11|Novartis Ag|A pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases.|

---

PT2976106T|2013-03-21|2021-05-26|Array Biopharma Inc|Combination therapy comprising a b-raf inhibitor and a second inhibitor|

---

TWI634114B|2013-05-08|2018-09-01|永恒生物科技公司|Furanone compounds as kinase inhibitors|

---

KR20160013028A|2013-05-30|2016-02-03|플렉시콘, 인코퍼레이티드|Compounds for kinase modulation, and indications therefor|

---

US10570204B2|2013-09-26|2020-02-25|The Medical College Of Wisconsin, Inc.|Methods for treating hematologic cancers|

---

WO2015084804A1|2013-12-03|2015-06-11|Novartis Ag|Combination of mdm2 inhibitor and braf inhibitor and their use|

---

WO2015095819A2|2013-12-20|2015-06-25|Biomed Valley Discoveries, Inc.|Cancer treatment using combinations of erk and raf inhibitors|

---

CA2934866A1|2013-12-23|2015-07-02|Novartis Ag|Pharmaceutical combinations|

---

JOP20200094A1|2014-01-24|2017-06-16|Dana Farber Cancer Inst Inc|Antibody molecules to pd-1 and uses thereof|

---

JOP20200096A1|2014-01-31|2017-06-16|Children’S Medical Center Corp|Antibody molecules to tim-3 and uses thereof|

---

DE102015103158A1|2014-03-04|2015-09-10|Bergische Universität Wuppertal|Compounds for the treatment of melanoma|

---

UY36032A|2014-03-14|2015-10-30|Novartis Ag|ANTIBODY MOLECULES THAT JOIN LAG-3 AND USES OF THE SAME|

---

WO2015145388A2|2014-03-27|2015-10-01|Novartis Ag|Methods of treating colorectal cancers harboring upstream wnt pathway mutations|

---

EP3143166A4|2014-05-16|2018-04-18|University of Massachusetts|Treating chronic myelogenous leukemia |

---

WO2016038582A1|2014-09-12|2016-03-17|Novartis Ag|Compounds and compositions as raf kinase inhibitors|

---

AU2015314756A1|2014-09-13|2017-03-16|Novartis Ag|Combination therapies of alk inhibitors|

---

US20170209574A1|2014-10-03|2017-07-27|Novartis Ag|Combination therapies|

---

MA41044A|2014-10-08|2017-08-15|Novartis Ag|COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT|

---

CR20170143A|2014-10-14|2017-06-19|Dana-Farber Cancer Inst Inc|ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME|

---

WO2016145102A1|2015-03-10|2016-09-15|Aduro Biotech, Inc.|Compositions and methods for activating "stimulator of interferon gene" -dependent signalling|

---

EP3316902A1|2015-07-29|2018-05-09|Novartis AG|Combination therapies comprising antibody molecules to tim-3|

---

EP3317301B1|2015-07-29|2021-04-07|Novartis AG|Combination therapies comprising antibody molecules to lag-3|

---

MX2018005550A|2015-11-03|2019-07-18|Janssen Biotech Inc|Antibodies specifically binding tim-3 and their uses.|

---

US20180371093A1|2015-12-17|2018-12-27|Novartis Ag|Antibody molecules to pd-1 and uses thereof|

---

WO2017117538A1|2015-12-30|2017-07-06|Saint Louis University|Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists|

---

RU2615986C1|2016-02-25|2017-04-12|Закрытое акционерное общество "Р-Фарм" |Substituted methyl-1h-pyrazol-4-yl]pyrimidin-2-ylamino}ethyl) carbamates, process for their preparation and application|

---

MX2018014973A|2016-06-03|2019-12-18|Array Biopharma Inc|Pharmaceutical combinations.|

---

US11098077B2|2016-07-05|2021-08-24|Chinook Therapeutics, Inc.|Locked nucleic acid cyclic dinucleotide compounds and uses thereof|

---

CA3048376A1|2016-12-27|2018-07-05|Riken|Bmp-signal-inhibiting compound|

---

EP3579872A1|2017-02-10|2019-12-18|INSERM |Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway|

---

UY37695A|2017-04-28|2018-11-30|Novartis Ag|BIS 2’-5’-RR- CYCLE DINUCLEOTIDE COMPOUND AND USES OF THE SAME|

---

CN107540699A|2017-10-16|2018-01-05|康化（上海）新药研发有限公司|A kind of synthetic method of the boric acid hydrochloride of 2 amino, 3 fluorine pyridine 4|

---

CA3086765A1|2017-12-28|2019-07-04|Tract Pharmaceuticals, Inc.|Stem cell culture systems for columnar epithelial stem cells, and uses related thereto|

---

WO2020011141A1|2018-07-12|2020-01-16|深圳市塔吉瑞生物医药有限公司|Diarylpyrazole compound, composition comprising same, and use thereof|

---

WO2020124397A1|2018-12-19|2020-06-25|Inventisbio Shanghai Ltd.|C-terminal src kinase inhibitors|

---

TW202038957A|2018-12-21|2020-11-01|日商第一三共股份有限公司|Combination of antibody-drug conjugate and kinase inhibitor|

---

CN113811303A|2019-05-16|2021-12-17|伊莱利利公司|For the treatment of BRAFV600EThree-medicine combination of ERK1/2 inhibitor, BRAF inhibitor and EGFR inhibitor for colorectal cancer|

---

WO2021110997A1|2019-12-05|2021-06-10|INSERM |N-thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors|

---

WO2022036176A1|2020-08-13|2022-02-17|Albert Einstein College Of Medicine|N-cyclyl-sulfonamides useful for inhibiting raf|

法律状态:
2021-04-13| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-06-15| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2021-06-29| B25A| Requested transfer of rights approved|Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) |

---

2021-07-20| B25A| Requested transfer of rights approved|Owner name: NOVARTIS AG (CH) |

---

2021-08-10| B25A| Requested transfer of rights approved|Owner name: ARRAY BIOPHARMA, INC. (US) |

---

2021-08-24| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2021-12-14| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2021-12-14| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US23807309P| true| 2009-08-28|2009-08-28|

---

US61/238,073|2009-08-28|

---

US31303910P| true| 2010-03-11|2010-03-11|

---

US61/313,039|2010-03-11|

---

PCT/US2010/046930|WO2011025927A1|2009-08-28|2010-08-27|Compounds and compositions as protein kinase inhibitors|

---